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7ABSTRACT
Objective: To compare the effectiveness of oral Azithromycin and
intravenous Ceftriaxone in the treatment of uncomplicated enteric fever
in children.
Methods: One hundred and twenty six children with proved
enteric fever were enrolled in this study. They were randomized into two
treatment groups. One group received oral Azithromycin (20mg/kg/day)
and the other group received parenteral Ceftriaxone (75mg/kg/day), both
of which were given for a duration of 7 days. The study population was
observed for fever defervescence, duration of hospital stay and relapse.
(In our study, 60 out of the 63 children in the Azithromycin group had
defervesced within 7days of treatment whereas the remaining 3 crossed
over. None in the Azithromycin group had relapsed. In the Ceftriaxone
group, 59 out of the 63 children defervesced within 7days of treatment
whereas remaining 4 cases were termed as treatment failures and required
longer duration of the same drug.
Results: The mean time for defervescence was 3.68±2.109 and
4.08±1.903days in the Azithromycin group and Ceftriaxone group
respectively. The mean duration of hospital stay was 7.35±2.604day in
the Azithromycin group and 9.44±0.249days in the Ceftriaxone group.
Among the 4 treatment failures in Ceftriaxone group, 2 cases relapsed
within 4week follow up period. There was no relapse in the Azithromycin
group.
Conclusion: Oral Azithromycin is as effective as intravenous
Ceftriaxone in treating uncomplicated typhoid fever in children with
respect to fever defervescence, duration of hospital stay and relapse.
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INTRODUCTION
Evolution of Typhoid fever
        The history of typhoid fever dates back to around 430–424 BC
during which time a dangerous plague killed nearly one third population
of Athens. Pericles, their leader was also a victim to this illness, hence
marking  an  end  to  the  Golden  Age  of  Pericles,  which  had  a  great
Athenian dominance in the ancient word of Greece. Thucydides, the
ancient historian also acquired the disease, but he lived to write about this
plague. His writings are the only evidence of this outbreak. Medical
scientists attributed the cause to epidemic typhus. In 2006 Papagrigorakis
MJ et al detected DNA sequences which were identical to those of the
bacterium which was responsible for typhoid fever, in dental pulp that
was extracted from a burial pit which dated back to the same time as the
outbreak.1
In Greek Typhos means smoke and hence typhus fever was named
after the smoke that was thought to have caused it. Typhoid means like
typhus.  Hence  this  name  was  given  to  this  disease.  The  first  to
differentiate clearly between typhus fever and typhoid in the year 1837
was William Wood Gerhard.
In 1856 William Bud, a British practitioner, demonstrated an agent
in  the  stools  of  patients  with  typhoid,  that  carried  the  disease  to  other
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patients. To prevent spread of the infection he had proposed boiling
contaminated linen, chemically disinfecting the discharges from typhoid
patients, having attendants wash their hands and also boiling of water and
milk during an epidemic.
In 1879, Karl Joseph Eberth, doctor and student of Rudolf
Virchow, discovered the bacillus in the abdominal lymph nodes and the
spleen of patients with typhoid fever. His discovery was then verified and
confirmed by German and English bacteriologists, including Robert
Koch. The genus “Salmonella” got its name after Daniel Elmer Salmon
who was an American pathologist. French physician Pierre Charles
Alexandre Louis proposed the name “typhoid fever”.2
In 1906 George Soper of New York City's health department
investigated six cases of typhoid that had occurred in one household. He
learned that a recently employed Irish cook had left abruptly after a stay
of 3 weeks. When he finally traced the cook he discovered that she had
been the cause of seven epidemics of typhoid in 6 years. Her name was
Mary Mallon, but she came to be known as Typhoid Mary. In all, she was
responsible for spreading the infection to at least 122 people, including 5
deaths. Mary Mallon, the first known case of a healthy carrier in the
United States, was kept in hospital for 3 years but she discharged herself
and against medical advice, took a job involving the handling of food;
this led to a further series of epidemics. Cholecystectomy was the only
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known treatment for carriers at the time, but she did not get it done. She
spent the last 23 years of her life in hospital.2
In 1937, Friz Kauffmann and Philip B. White in 1926 introduced
the Kauffmann – White classification system after studying the antigenic
structures of both typhoid and typhoid –like bacteria in detail. The
isolation of Salmonella is based on this classification system which
utilizes antigenic specificities of H, O and Vi antigens.2
Magnitude of the problem
Typhoid fever is a major global public health problem. In view of
the similarities in clinical picture as seen with many other febrile
infections, it is difficult to estimate its actual impact. The global
incidence of typhoid fever was arrived at based on literature and large
vaccine field trials. It has been estimated that 21.6 million cases and
about 2.5 lakh deaths occur worldwide annually. Almost 80% of which
occur in Asia and in developing countries such as India, its incidence
varies from 102-2219/1 lakh population. In endemic areas, about 1/3rd to
1/4th of pediatric enteric fever cases are less than 5yrs with 6-21% cases
being less than 2yrs of age.
The ratio of infection caused by S. typhi: S. paratyphi was about
10:1 in reports from most countries. The age group at risk of developing
the infection during large outbreaks and in areas of endemicity and was 3
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to 19 years. Nevertheless, clinically apparent bacteremia in children aged
less than three years has been described from India, Bangladesh, Nigeria,
Jordan, etc. Chronic carrier state has been observed in about 1-5% of
patients who had suffered from acute typhoid infection. These individuals
harbored the organism in the gall bladder. The risk of becoming a carrier
was more in gall bladder disease, increasing with age and was greater in
females when compared to men. 3, 4, 5, 6
The Organism:
The organism implicated in the causation of enteric fever is
Salmonella typhi, a gram negative bacillus. They vary in size between 1-3
micro meters to 0.5micro meters. They are motile with peritrichate
flagella. They also possess fimbriae. They are aerobes and facultative
anaerobes. The disease caused by Salmonella paratyphi A and B is similar
to S. typhi but less severe.
Colony characteristics:
The colonies of Salmonella are classically described as smooth,
non- hemolytic and non-lactose fermenting on various special culture
media. 7
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Table 1: Clinical features of Typhoid fever in children.8
                   Symptoms                      Signs
1. High grade fever Toxicity
2. Anorexia Coated tongue
3. Vomiting Pallor
4. Diarrhoea Rose spots
5. Abdominal pain Abdominal distension
6. Constipation Hepatomegaly
7. Headache Splenomegaly
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Complications of enteric fever in children:
The most common complications encountered in typhoid fever are
(in order of decreasing presentation):
1. Central nervous system involvement is seen as psychosis, delirium,
meningism, seizures; CNS infections like meningitis, subdural
empyema, cerebral abscess, meningitis, ventriculitis. Other
complications also seen are motor neuron disorders, ataxia and
Guillain Barré syndrome.
2. Gastro intestinal system: Next most commonly involved is the GI
system. The child can usually present with hepatitis, cholecystitis
and paralytic ileus. Rarely seen are hepatic abscesses, splenic
abscess, peritonitis etc.
3. Pulmonary involvement is seen as bronchitis, pneumonia and
empyema or broncho pleural fistula.
4. The cardiac complications of typhoid fever include endocarditis,
pericarditis, myocarditis and congestive cardiac failure.
5. Genitourinary involvement is seen in less than 1% of the cases, and
includes UTI, renal abscess, pelvic infections, testicular abscess,
epididymitis and prostatitis.
6. Bone and joint involvement is seen as either septic arthritis or
osteomyelitis.
16
7. Other less commonly encountered complications but described in
literature are cutaneous vasculitis, psoas abscess, gluteal abscess
and Hemophagocytosis syndrome. 8
Emergence of resistance and Quest for newer drugs
In 1948, Theodore Woodword showed that Chloramphenicol
sterilized the blood culture of enteric fever patients. In view of this
property, this drug was most commonly prescribed for treating typhoid
fever. Within 2yrs (1950) of its advent, S. typhi isolates resistant to
Chloramphenicol started appearing in UK, this was attributed to its
indiscriminate usage. In the 60s, sporadic cases of Chloramphenicol
resistant typhoid fever were reported from all over the world, including
India. The first epidemic of chloramphenicol resistant enteric fever
occurred in Mexico in 1972, followed by India (1972), Vietnam (1973)
and Korea (1977). 3, 4
Cotrimoxazole was used as an effective alternative to
Chloramphenicol in treating these resistant strains till 1975. But
resistance to Cotrimoxazole started appearing in France. Strains resistant
to all 3 first line drugs i.e. Ampicillin, Cotrimoxazole and
Chloramphenicol, started appearing by late 1980s. MDRST (multidrug
resistant salmonella typhi) was seen in epidemic proportions for which
fluoroquinolones were used worldwide. The first case of S.typhi resistant
to fluoroquinolones was reported in 1992 from the UK and
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fluoroquinolone resistant cases were also increasingly reported from
several other countries and India. 3, 4
With the increasing development of Nalidixic acid (Quinolone)
resistance  among S.  typhi,  3rd generation Cephalosporins are being used
in the management of MDRST.
Intravenous Ceftriaxone administration is associated with high
cost, prolonged hospitalization and morbidity due to intra venous drug
use. Of late Salmonella strains resistant to Ceftriaxone have started
appearing.3, 4, 5
In  view  of  emergence  of  MDRST  and  NARST  (Nalidixic  acid
resistant salmonella typhi), a number of studies were carried out
worldwide  to  study  the  clinical  and  epidemiological  profile  of  MDRST
and  NARST,  including  the  drug  sensitivity  and  resistance  patterns  of  S.
typhi, thereby beginning the quest for newer drugs.
The Indian Scenario
In  India,  MDR  Salmonella  typhi  (MDRST)  was  first  reported  in
1988 from Mumbai. Again in March 1990, an outbreak of MDRST
occurred in Mumbai which was called Dombivli fever. In the same year
there  was  an  outbreak  of  MDRST in  New Delhi.  The  S.  typhi  strains  in
these two outbreaks were found to be sensitive to ciprofloxacin. MDRST
was also reported in the mid-1990s from Bangalore which was found to
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be as high as 95%. In 1999, similar resistance to the 3 first line drugs was
reported from Manipal. It was found that all these strains were sensitive
to Fluoroquinolones and Ceftriaxone. During these outbreaks,
Ciprofloxacin was considered as the first drug of choice for its high cure
rate without any relapse or carrier state. Over the subsequent few years,
there was an increase in Ciprofloxacin resistance.
In 2000,  Das et  al  from Orissa found that  2.5% of S.  typhi  strains
were resistant to Ciprofloxacin. In a prospective study done by Kumar et
al in Delhi, there was a sequential increase in MDRST from 34% to 66%
over 10 years (1999-2009). They also reported a gradual increase in
Fluoroquinolone resistance over these 7 years.
As the years progressed, several isolated reports of resistance to
Ceftriaxone were reported from different parts of India. These
observations of increasing ciprofloxacin resistance and early evidence of
Ceftriaxone resistance correspond with the global picture. 4, 5, 6
Drugs used in the management of typhoid fever:
Chloramphenicol:
Mechanism of action of Chloramphenicol is by inhibition of
microbial protein synthesis. Chloramphenicol inhibits peptidyl transferase
step of protein synthesis by binding reversibly to 50S subunit of the
bacterial ribosome. It is bacteriostatic and has broad-spectrum activity
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against both aerobic and anaerobic organisms; and gram-positive and
gram-negative organisms. Minimum inhibitory concentration for most
gram positive organisms is 1–10 ?g/mL, and for gram-negative bacteria it
is 0.2–5 ?g/mL. Resistance to Chloramphenicol occurs due to the
production of acetyl transferase by the organism which is a plasmid-
encoded enzyme resulting in drug inactivation. Its therapeutic dose is 50–
100 mg/kg/d. One gram of the drug achieves a serum concentration of 10-
15?g/mL. Its prodrug is Chloramphenicol palmitate which gets
hydrolyzed in the intestine to Chloramphenicol. Chloramphenicol
succinate is also a prodrug used in parenteral preparations, which is
hydrolyzed to Chloramphenicol, producing serum concentrations lower
than that achieved with oral drug. It has a large volume of distribution.
Penetration of the drug through the cell membranes occurs readily.
Inactivation of the drug occurs in the liver both by glucuronic acid
conjugation and by conversion to inactive aryl amines. Drug elimination
occurs in the urine, bile and feces. Drug dose needs to be adjusted in
hepatic failure, newborns and preterm infants. Chloramphenicol is rarely
used now a days because of the rapidly developing resistance and
toxicities.9
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Cotrimoxazole:
Trimethoprim is a tri methoxy benzyl pyrimidine and its
mechanism of action is by selective inhibition of bacterial dihydrofolic
acid reductase, an important step in the synthesis of nuclear material.
Pyrimethamine is also a benzyl pyrimidine. It acts by selectively
inhibiting the dihydrofolic acid reductase of only microorganisms. The
combination of a Sulfonamide with Trimethoprim or Pyrimethamine
results in synergism thereby enhancing drug potency. The combination
becomes bactericidal though the individual drugs if used alone are
bacteriostatic. It is usually given orally though injectable formulations of
Trimethoprim-sulfamethoxazole are currently available. Both the drugs
are excreted through urine and require dose adjustments in cases with
decreased creatinine clearance. Drug resistance to Cotrimoxazole can be
due to:
1. Dihydrofolate reductase over production OR
2. Decreased drug binding due to production of an altered reductase
OR
3. Decreased cell permeability OR
4. By plasmid-encoded Trimethoprim-resistant dihydrofolate
reductases.
Trimethoprim causes leukopenia, granulocytopenia and
megaloblastic anemia due to its antifolate activity.10
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Fluoroquinolones:
Fluoroquinolones are synthetic fluorinated analogs of Nalidixic
acid. Its mechanism of action is mainly by inhibition of bacterial DNA
synthesis which is brought about by blocking DNA gyrase and
topoisomerase IV. This prevents the positively supercoiled structure of
DNA from relaxing, which has a role in normal transcription and
replication of the nuclear material. All these interfere with the normal
replication and distribution of nuclear material during cell division.
Resistance  is  either  due  to  one  or  more  point  mutations  in
quinolone binding region of the target enzyme or a change in
permeability of the organism. Recently two types of plasmid mediated
resistance have been described. One type utilizes Qnr proteins, which
protects the DNA gyrase from fluoroquinolones. The other type is a
variant of aminoglycoside acetyl transferase capable of making
modifications to Ciprofloxacin. Cross resistance is a well-known entity in
this group of drugs.
Their bioavailability is about 80–95% after oral administration and
has  a  large  volume  of  distribution.  Its  t½  is  between  3-10  hours.  These
drugs have relatively long plasma t½ enabling once a day dosing.
Dose needs to be adjusted in renal failure since the main route of
excretion is through urine.10
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Ampicillin:
Its antibacterial spectrum comprises those of penicillin as well as
has gram-negative coverage. They are susceptible to hydrolysis by beta
lactamases. Hence it is usually administered in combination with a beta
lactamase inhibitor like Clavulanic acid, Tazobactam or Sulbactam to
extend its spectrum of activity. Non allergic rash is caused by Ampicillin
and amoxicillin. Inappropriate prescription of amino penicillins for viral
illness results in such a rash frequently.11
Table 3: Treatment of uncomplicated typhoid fever: 8, 12
Susceptibility Optimal therapy Alternative effective drug
Fully sensitive
Multidrug
resistant
Antibiotic Daily
dose
(mg/kg)
Days Antibiotic Daily dose
(mg/kg)
Days
Chloramphenicol
(or)
Amoxicillin
50-75
75-100
14-21
14
Fluoroquinolon
es, e.g.,
Ofloxacin (or)
Ciprofloxacin
15 5-7
Fluoroquinolones
(or) Cefixime
15
15-20
5-7
7-14
Azithromycin
(or)
Cefixime
20
15-20
7
7-14
Quinolone
resistant
Azithromycin (or)
Ceftriaxone
8-10
75
7
10-14
Cefixime 20 7-14
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Ceftriaxone Vs Azithromycin
Ceftriaxone
It is a 3rd generation Cephalosporin with broad-spectrum of activity
against both gram positive and negative organisms. Its main mechanism
of action is by inhibiting the bacterial cell wall synthesis by binding to
penicillin binding proteins. It is bactericidal but is inactive against
organisms producing extended spectrum beta lactamases.11
Azithromycin
Azithromycin is a macrolide antibiotic with the advantages of
excellent intracellular penetration and long t½ of about 72hrs.This helps
in administering the drug once a day. Several clinical trials have studied
and found that it is more potent than first-line drugs and other macrolides
in  treating  salmonella  infection.  It  has  a  MIC  of  8?g/mL  (range  4  to
16?g/mL).
Food, aluminium and magnesium antacids interfere with its
absorption from the gut.9
Prevention of typhoid fever
The major route of transmission of typhoid fever is feco-oral.
Infection can be acquired by consuming water or food that is
contaminated by the organism. Therefore main modalities of prevention
24
are by promoting personal hygiene, ensuring access to safe and clean
drinking water and also by propagating clean food handling practices.
? Safe water: Typhoid fever can be acquired by drinking unclean
water. Every effort must be taken towards providing clean,
chlorinated water to the community. The water should be clear and
non-foul smelling. In the community, people should take care of
the hygiene around water sources and drinking water should be
boiled before consuming.
? Food safety: At home, the person involved with cooking should
ensure proper hand washing before cooking and raw fruits and
vegetables should be washed well and cooked well before
consumption. As mentioned earlier, Typhoid Mary was responsible
for epidemics as a chronic carrier, by way of serving contaminated
food. Hence people involved in food industry should be screened
for chronic carrier state and should not be allowed to resume their
duties until they have had three negative stool cultures taken at
least one month apart.
? Sanitation: Proper sanitation plays an important role in breaking
the chain of transmission of the infecting pathogen. This can be
achieved by:
* Sanitary latrines should be used for defecation.
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* Ensure safe human waste disposal.
* Discourage the use of human excreta as fertilizers
? Health Education: has a pivotal role in preventing any
communicable disease. Health education should address all age
groups  and  all  socio  economic  strata.  It  should  aim  at  promoting
personal and community hygiene, use of clean water, use of
sanitary latrine, proper hand washing techniques, etc. People
should be educated regarding the use of freshly prepared food
rather than reheating them. Health education can be imparted to the
community by way of role plays, community talks, mass media
like newspapers, TV, radio and internet; and school health
programmes. 13
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REVIEW OF LITERATURE
1. Articles related to clinical features of typhoid fever in children
          In a study conducted by Ramaswamy et al14 from south India,
which spanned over 3years (2005-2008), it was found that three hundred
and sixteen children were treated as enteric fever out of forty five
thousand one hundred and ninety six hospital admissions, this accounted
for seven per one thousand admissions. Among the 316 children enrolled,
male: female ratio was 1.29:1. Maximum number of cases (38%) were
found to occur between January to April. Most common age group
affected was 5-10yrs (33.5%) with 1.8 % cases being less than 1 year of
age, 16 % cases between 1-2 years, 32 % cases between 2-5 years and
15.8 % cases more than 10 years of age. The predominant symptom and
sign was vomiting and hepatomegaly seen in 49% and 71% cases
respectively. Other symptoms and signs observed were diarrhea,
splenomegaly, and toxemia; observed in 29%, 34% and 16% cases
respectively. Leukocytosis was more common than leucopenia, seen in
12% and 8% of the cases respectively. They had found statistically
significant eosinopenia in 72 % of cases. On analyzing the liver enzyme
levels they found mild elevation of serum transaminases in majority of
the cases (60%). On reviewing the ultrasound abdomen report they found
thirteen children to have free fluid in the abdomen and about fifteen
children to have gall bladder disease, which was evidenced by gall
bladder hydrops, thickening and sludge. The complications encountered
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in their study group was Systemic inflammatory response syndrome,
hepatitis, septic shock, meningitis, GI bleed, osteomyelitis, myocarditis
and Infection associated hemophagocytic lympho histiocytosis.
Lalitha et al15, in their retrospective study had reviewed case
records of children in the age group one month to 18 years with culture
proven typhoid fever, between January to December 2007. They observed
that during the specified period, 100 children had culture proven
Salmonella infection out of thirteen thousand two hundred and sixty five
admissions, male: female ratio being 2:1. Majority (51%) of the children
was below 5 years, 32% were between 5 and 10 years and 17% were
above 10 years. Cases clustered between the months of September and
December. Fever (100%), vomiting (54%) and loose stools (31%) were
the  predominant  symptoms  seen.  Common  clinical  signs  observed  were
hepatomegaly (72%), splenomegaly (31%), and coated tongue (24%).
Eosinopenia was observed in 67%. None had sonographical evidence of
cholelithiasis.
          In a retrospective study by Gosai et al [16] done at Ahmedabad, case
records of 150 children with clinical enteric fever or proven cases of
typhoid fever, were reviewed over a period of one year. They observed
that there were 88 male and 62 female patients, in the age group 2-12
years. Fever, abdominal pain, vomiting and headache were the
predominant symptoms observed. Hepatomegaly was more common than
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splenomegaly. Relative bradycardia and rose spots were rarely seen in
children. Fever, Toxic look, coated tongue and hepatosplenomegaly were
common clinical signs of clinical presentation in children. Hepatitis,
Bronchitis and Encephalopathy were commonly observed complications
of Multidrug resistant typhoid fever in this study.
A retrospective analysis of 106 individuals who were culture
positive for Salmonella typhi was done by Kumar et al17 at Manipal. They
observed that majority (78.3%) was males and 21.7% were females. Most
common age affected was between 15-30 years. The mean age of the
patients was 28.8±1.32 years. The average duration of hospital stay was
8.7 days. All patients in the study had fever. The common symptoms
were headache, vomiting, abdominal pain and diarrhea which were seen
in 63 (59.4%), 30 (28.3%), 21 (19.8%) and 29 (27.4%) patients,
respectively. They observed splenomegaly in 47 (44.3%), hepatomegaly
in 42 (39.6%) while hepatosplenomegaly was seen in 23 (21.7%).
Abdominal tenderness was another common presenting sign seen in 23
(21.7%) of cases. Widal was concomitantly positive in 73 (68.9%) cases.
Liver enzymes (alanine aminotransferase, aspartate aminotransferase and
alkaline phosphatase) were raised in 52 (49.1%) patients. Complications
were very few. Only one patient each had myocarditis, encephalitis,
gastrointestinal bleed and gastrointestinal perforation as complications.
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2. Articles related to Epidemiology
Ram et al18 conducted  a  study  in  a  small  slum  of  Bangladesh  to
find out risk factors for typhoid fever in that part of the world. They
found that drinking unboiled water at home; foul-smelling water source,
eating substandard ice creams, milk products, milk sweets, consuming
fruits and vegetables without washing were all associated with the illness.
Using a latrine for defecation was found to be significantly protective.
Following typhoid fever outbreak in a slum in West Bengal, in
February 2007, Bhunia et al19 attempted to find out the cause for the
outbreak. They identified that the suspected cases clustered around three
public taps and were consuming milk products from a common sweet
shop. The food handler in that particular sweet shop had suffered from
enteric fever in January that year and was probably the Typhoid Mary in
these cases. The pipelines of drinking water and sewage system ran next
to each other and the water from these pipes had revealed fecal
contamination.
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3. Articles related to Azithromycin use in typhoid fever
Anju et al20 conducted a multicenter study to evaluate the efficacy
and safety of Azithromycin in the management of uncomplicated typhoid
fever. Mean day of response was 3.45±1.97 days. They observed 100%
clinical and microbiological cure without any relapse. None in this study
had any adverse events. Hence they concluded that oral Azithromycin
was safe and effective in the treatment of uncomplicated typhoid fever.
Dheeraj Shah21 included 7 randomized trials in his systematic
review. The seven trials had enrolled seven hundred and seventy three
confirmed cases of uncomplicated typhoid or paratyphoid fever. Three
trials each were conducted in Vietnam, Egypt and one reported from
India was a multicentric trial. Three out of the seven trials included adults
only, two trials included children only, and two other trials included both.
Many cases included in these trials had infections with MDRST and
NARST. Ceftriaxone and Ofloxacin were compared with Azithromycin,
in 2 trials. Azithromycin was compared with Ciprofloxacin in one trial,
with Gatifloxacin in a second trial and with Chloramphenicol in the third
one.
On comparing with Fluoroquinolones, Azithromycin significantly
reduced clinical failure, duration of hospital stay and number of relapse.
The authors concluded that Azithromycin was more effective than
fluoroquinolones for treatment of enteric fever including MDRST and
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NARST and may be much better than Ceftriaxone in reducing the number
of relapse.21
In a study done by Hussain et al22 in  Shaikh  Zayed  Hospital,
Lahore, Pakistan, during the year 2011, 83 confirmed cases of typhoid
fever were enrolled and treated with oral Azithromycin 20mg/kg/day for
7days.Out of the 83 children enrolled, 75(90.36%) completed the study.
Male to female ratio was 1.6:1 in the age group of 8-12 years. S.typhi was
isolated in 5(6.67%) cases and all achieved bacteriological cure by seven
days. Mean duration of fever at presentation was 5±3.07 days. Seventy
one cases had clinical cure with mean day of response being 4 days. The
authors concluded that Azithromycin was found to be safe and effective
in the treatment of uncomplicated typhoid fever in a dose of 20mg/kg/day
per oral once a day for seven days.
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4. Articles comparing Azithromycin with Fluoroquinolones
Girgis et al23, in their study conducted at Egypt in 1999, comparing
Azithromycin and Ciprofloxacin in uncomplicated typhoid fever in adults
observed that the time taken for defervescence in Azithromycin group
was 3.8 ± 1.1days and 3.3 ± 1.0days with Ciprofloxacin. There were no
relapses in either group. They concluded that Azithromycin and
Ciprofloxacin had similar efficacy, against both sensitive organisms and
MDRST.
In yet another study by Parry et al24 from Vietnam, Azithromycin
was studied as a single drug as well as in combination with Ofloxacin and
with Ofloxacin alone, in three groups of children respectively. It was
found that the clinical cure rate was 64%, 76% and 82% with Ofloxacin,
Ofloxacin-Azithromycin combination, and Azithromycin alone,
respectively (P 0.053). The mean fever clearance time for patients treated
with Azithromycin [5.8±0.7days] was shorter than that for patients
treated with Ofloxacin-Azithromycin [7.1±1.1days] and Ofloxacin
[8.2±1days] (P < 0.001). Following this study Parry et al found that
uncomplicated typhoid fever can be treated with successfully a 7-day
course of Azithromycin.
In a prospective, randomized, open labelled study conducted by
Chandey et al25, to compare the efficacy and safety of Azithromycin with
Ofloxacin in patients with uncomplicated typhoid fever, 40 adult patients
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with bacteriological or serological diagnosis of typhoid fever were
included from Medicine out-patient department at Government medical
college, Amritsar, India. The study population was randomized into two
groups of twenty patients each. Group 1 was treated with Ofloxacin and
group 2 with Azithromycin. Nineteen out of 20 patients from group one
defervesced with mean fever defervescence of 3.68 days while all 20
patients from group two defervesced with a mean fever defervescence of
3.65 days. They concluded that both Ofloxacin and Azithromycin were
almost equally efficacious and safe in treatment of typhoid fever with no
major adverse effect and Azithromycin is an effective alternative in
conditions where Ofloxacin is contraindicated as in quinolone resistant
cases of typhoid fever, children and pregnant women.
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5. Articles comparing  Azithromycin with Chloramphenicol
       Butler et al [26] randomized 77 adult patients with typhoid fever into
two treatment groups, Azithromycin and Chloramphenicol. 42 patients in
Azithromycin group received the drug at 500mg/day PO OD for 7days
and 35 patients in the Chloramphenicol group received the drug at 2-3g
PO OD in four divided doses for 14days. 37 patients (88%) in the
Azithromycin group and 30 patients (86%) in the chloramphenicol group
responded within 8days. By 14days after start of therapy, all patients in
the Azithromycin group (100%) and all except 2 cases in the
Chloramphenicol group (94%) were cured. They concluded that
Azithromycin given once daily for 7days was effective in treating both
Chloramphenicol resistant as well as Chloramphenicol sensitive
Salmonella infection.
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6. Articles comparing Azithromycin with Ceftriaxone
      In 2004 Frenck et al27 conducted a study to compare the effectiveness
of oral Azithromycin and parenteral Ceftriaxone in the treatment of
uncomplicated enteric fever. They had enrolled 149 children and
adolescents between 3–17 years of age with clinical typhoid fever. These
children were randomized into two treatment groups. One group received
oral Azithromycin 20mg/kg/day OD and the other group received
parenteral Ceftriaxone 75mg/kg/day. Both the drugs were given for
duration of 5days. Complete cure was observed in 30 (94%) of 32
patients in the Azithromycin group and 35 (97%) of 36 patients in the
Ceftriaxone group. Mean fever clearance time was 4.5±1.9 days in the
Azithromycin group and 3.6±1.6 days in the Ceftriaxone group. Mean
time to achieve microbiological cure was longer in the Azithromycin
group than in the Ceftriaxone group. None in the Azithromycin group
relapsed as against 6 relapses in the Ceftriaxone group. They concluded
that a 5-day course of Azithromycin was an effective treatment for
uncomplicated typhoid fever in children and adolescents.
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STUDY
JUSTIFICATION
38
STUDY JUSTIFICATION
Enteric fever is endemic in most parts of India. With the changing
pattern in the presentation of enteric fever in different age groups and the
sensitivity trends of S.typhi, pediatricians are faced with multiple
challenges in their day to day practice.
Enteric fever still continues to be a major global public health
problem despite the development of newer antibacterial drugs, the recent
upsurge in multidrug resistant S.typhi infection has made the treatment of
enteric fever a difficult problem.
With the rise in MDRST and NARST, parenteral Ceftriaxone is
being increasingly used for the management of typhoid fever in children,
which is associated with prolonged hospitalization, morbidity due to
intravenous drug administration and loss of school days for children, loss
of working days and hence loss of pay for parents.
Most parents of the children coming to our hospital are working
mothers, who are already struggling to make the ends meet.
Before planning this study, the practice in our hospital was to treat
all cases of Enteric fever with intra venous Ceftriaxone. We noticed
several morbidities in children related to IV administration of the drug
like pain, fever due to thrombophlebitis etc. We also observed that the
families had to struggle to cope up with taking care of the hospitalized
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sick child as well as to make arrangements to manage other family
members at home. They had to keep themselves away from work thereby
losing their income too. An effective orally available drug for enteric
fever would be able to overcome at least some of the problems faced by
the family.
Hence this study was undertaken to find out if oral Azithromycin is
effective in reducing the time taken for defervescence and in reducing the
duration of hospitalization.
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MATERIAL AND METHODS
Aims and Objectives
Aim of the study:
To  study  the  effectiveness  of  oral  Azithromycin  as  compared  to
parenteral Ceftriaxone in the treatment of uncomplicated Enteric fever.
Objectives of the study :
Primary objective:  is  to  compare  the  effectiveness  of  oral
Azithromycin and intravenous Ceftriaxone in the treatment of
uncomplicated enteric fever in children.
Secondary objective: is to study the clinical and epidemiological
profile of enteric fever in children.
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Methodology
Study design:
Prospective, Randomized open labeled study
Place of study:
Department of Pediatrics, ESIC Medical College & PGIMSR, K.K
Nagar, Chennai – 78
Period of study:
July 2013 – August 2014
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Sample size:
63 in each group. The sample size was calculated by Convenient
sampling method with OR – 6 and CI 95%, using openepi software.
Sample size calculation
2-sided significance level(1-alpha): 95
Power (1-beta, % chance of detecting): 80
Ratio of sample size, Unexposed to Exposed: 1
Percent of Unexposed with Outcome: 5
Percent of Exposed with Outcome: 24
Odds Ratio: 6
Risk/Prevalence Ratio: 4.8
Risk/Prevalence difference: 19
Kelsey Fleiss Fleiss with CC
Sample Size - Exposed 54 53 63
Sample Size-unexposed 54 53 63
Total sample size 108 106 126
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Study population:
The study population included all Paediatric ward in patients
between 2 to 12 years of age with proven typhoid fever.
Inclusion Criteria:
Children admitted to the Pediatric ward with fever and
1. A positive Widal test or with rising titres of O and H antigens.   OR
2. Blood / urine / stool culture positive for Salmonella
Were included in the study.
Exclusion Criteria:
1. Children with complications such as jaundice, severe
gastrointestinal bleeding, myocarditis, intestinal perforation, renal
failure, pneumonia,  an altered level of consciousness or shock, etc.
2. Hypersensitivity to either of the drugs &
3. Lack of parental consent.
Were excluded from the study.
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Procedure
Among the children presenting with fever, a detailed history taking
and complete clinical examination was done. After obtaining consent
from the parents, blood samples were drawn for complete blood counts,
Widal test, blood culture and sensitivity, and also for other tests (smear
for MP, Dengue serology etc.) to rule out other causes of acute febrile
illness. Based on the duration of fever, urine and stool cultures were also
done.
Once the investigation results were obtained, only proven cases of
typhoid fever (i.e. positive Widal test or culture positive for Salmonella)
were selected. Informed consent was obtained from the parents before
recruiting their children into this study. All clinical findings, results of
investigations, treatment details and follow up were documented in a pre-
structured study proforma.
The children were divided into two groups by lots method. The lots
were prepared as blocks of five in each treatment group. Closed
envelopes containing the treatment group into which the child would fall
comprised the lots. The children or their parents picked up the lot and the
child was treated as per the treatment mentioned in the envelope.
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Children under the Ceftriaxone group were administered Inj.
Ceftriaxone 75mg/kg/day BD for seven days. And those under the
Azithromycin group received Azithromycin suspension or tablet
20mg/kg/day as a single dose for seven days. Children in both the groups
were subjected to clinical examination daily during their hospital stay and
were observed for fever clearance. When there was failure to respond to
either  drug  by  seven  days  as  evidenced  by  persistence  of  fever,  it  was
considered as treatment failure.
Children who failed to respond to Azithromycin crossed over to
Ceftriaxone and were treated with the above mentioned dose of
Ceftriaxone till twenty four to forty eight hours after defervescence.
Children who failed to respond to Ceftriaxone were considered as
treatment failure and continued to receive the same dose of Ceftriaxone
till twenty four to forty eight hours after defervescence.
When defervescence occurred within seven days, children in the
Azithromycin group were observed for 24hrs after fever clearance and
discharged with the drug to be continued at home for the remainder days
and were asked to review if fever recurred. But children in the
Ceftriaxone group required hospital stay of seven days for completion of
treatment, despite fever clearance.
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After discharge the children in both the groups were reviewed at
thirty  days  for  a  stool  culture  or  earlier  if  they  had  recurrence  of  fever.
Children who had recurrence of fever were again investigated for typhoid
fever and if positive were considered as relapse.
Material used in this study:
Complete blood counts:
This was done using automated five part cell counter and the
results were analyzed by flow cytometry.
Diagram 1: 5 Part cell counter used
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Widal test:
It  can  be  done  in  two  ways  –  as  tube  agglutination  and  slide
agglutination test. In our study, serological diagnosis of typhoid fever was
made by using tube agglutination test. This test was named after Georges
Fernand Isidore Widal, a French physician and bacteriologist. The
principle behind this test is that patients with active Salmonella infection
would express antibodies in their sera which react and agglutinate serial
doubling dilutions of killed, colored Salmonella antigens. S.typhi O and
S.typhi H antigens are prepared using Salmonella typhi 901 strain. The
antigen O of S. typhi and that of paratyphi A and B have cross-reactivity
with each other. The control tubes are examined first, which will not
show any agglutination. The O antigen agglutination is seen as a “matt”
or “carpet” at the bottom of the tube. The H antigen agglutination is seen
as loose, wooly or cottony. The highest dilution of serum producing a
positive agglutination is considered as titre. The titres for all the antigens
are made note of.
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Diagram 2: Widal test - tube agglutination test
Interpretation of Widal test: A Single titre is usually not of much
importance. A rise in titre is more significant than a one test value. A titre
is said to be significant if it is 100 or more for O antigen and 200 or more
for H antigens.
There will be no rise in titre if the patient was already treated with
antibiotic, instead there may be fall in titre. Results may not be positive
even in patients treated with antibiotics in early stages of the illness.
False positive reactions are seen in vaccinated individuals, this can
be differentiated from true typhoid illness by repeating this test after one
week. A rising titre will be seen in true untreated infection whereas
vaccinated individuals show no rise in titre.
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Anamnestic reaction is seen in individuals with past salmonella
infection. These individuals develop antibodies against Salmonella when
they acquire infection with closely related organism. This reaction is
identified by repeating the test after a week and demonstrating a lack of
rise in titre. False positive reactions are observed if the antigen
suspension contains fimbrial antigen.
Blood culture:
Under all aseptic precautions 2ml blood was drawn by
venipuncture and was inoculated immediately onto a blood culture bottle
(Diagram 2). The sample bottles were sent immediately to the
microbiology laboratory, where these bottles were incubated at 37°C and
checked for biochemical reactions like gas formation, turbidity and other
evidence of growth after one, two and three days. When there was no
evidence of growth even after 72 hours, the culture was reported as sterile
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Diagram 2: Culture bottle used
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Diagram 4: Incubator used
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Drug sensitivity:
After confirming the growth, antibiotic sensitivity was done using
Kirby-Baur technique on Muller-Hinton agar. A loopful of growth was
taken from the agar and inoculated in peptone water; after 10 minutes,
this peptone water was poured over the Muller-Hinton agar to cover its
entire surface; the excess peptone water was poured into the bottle.
Then antibiotic discs like ampicillin, chloramphenicol, Nalidixic
acid etc., were plated and incubated for 24 hours at 37?C. Then zone of
inhibition was measured and results were interpreted.
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Diagram 5: Drug sensitivity testing by disc diffusion
Ceftriaxone injection used:
Diagram 6: Ceftriaxone injection
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Azithromycin tablets and suspension used:
Diagram 7: Azithromycin preparations used
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Outcome measures:
The effectiveness of the treatment was assessed by the:
 a) Time taken for fever clearance.
 b) Duration of hospital stay and
 c) Relapse
57
Statistical Analysis used:
In the above study, statistical methods were applied for quantitative
data and qualitative data. Quantitative data was presented by N, Mean,
Standard Deviation and Range. For qualitative data, frequency count N
and percentage were tabulated in tables.
To analyze the data, appropriate statistical tests were applied. To
compare the difference between two means, independent t test was used.
All the statistical analysis had been done by using statistical
software SPSS (version 16.0). Other data was displayed by various tables
and charts by using Microsoft excel (windows 7).
*Significant at p < 0.05
**very significant p <0.01
***highly significant p < 0.001
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RESULTS
On analysis of 126 cases enrolled in this study, the following
observations were seen,
DEMOGRAPHIC FACTORS
Age Distribution:
Among the 126 participants enrolled in the study, the mean age
was 6.98±3.25years. Out of which 44.4% were in the age group 2-6years
and 55.6% in the age group 7-12years.
Mean age in Azithromycin and Ceftriaxone groups were
7.21±3.26years and 6.75±3.24years respectively. In the Azithromycin
group, about 40% (n=25) cases were between 2-6years and 60% (n=38)
were between 7-12years. In the Ceftriaxone group, about 49.2% (n=31)
cases were between 2-6years and 50.8% (n=32) cases were between 7-
12years.
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Figure 1: Age distribution (n=126)
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Figure 2: Age distribution (Azithromycin vs Ceftriaxone)
Gender Distribution:
It was observed that 56.3% (n=71) of the total children were boys
and 43.6% (n=55) were girls.
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Figure 3: Gender distribution (n=126)
Out of  the 63 cases 57% (n=36) were boys and 43% (n=27) were
girls in the Azithromycin group whereas there were 56% (n=35) boys and
44% (n=28) girls in the Ceftriaxone group.
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Figure 4: Gender distribution (Azithromycin vs Ceftriaxone)
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Duration of fever at admission:
It was observed that the mean duration of fever among all children,
at the time of admission was 7.66±3.39 days and it was predominantly
intermittent type of fever, being associated with chills and rigors in
44.44% (n=56) of the cases. In the Azithromycin group it was 7.4±2.95
days and in the Ceftriaxone group it was 7.92±3.79 days, associated with
chills and rigors in 44% (n=28) of cases in both the groups.
In the Azithromycin group, 6% (n=4) cases presented within 3 days
of fever, 59% (n=37) cases presented between 3 to 7 days and 35 (n=22)
cases presented with fever for more than 7days. In the Ceftriaxone group,
5% (n=3) cases presented with fever for 3 days, 54% (n=34) presented
between 3 to 7 days and 41% (n=26) cases had fever for more than 7 days
at admission.
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Figure 5: Duration of fever at admission (Azithromycin vs
Ceftriaxone)
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Prior treatment with antibiotics:
History of prior treatment with antibiotics was observed in 27% of
total cases (n=34), 32% (n=20) of cases in the Ceftriaxone group and
22% (n=14) of cases in the Azithromycin group.
The antibiotics used were either oral Cephalosporins or
Fluoroquinolones.
Epidemiological profile:
In 24.6% (n=31) of the cases, there was history of other family
member being affected with typhoid fever at  about  the same time as the
index case. Twenty five percent (n=16) of the cases in Azithromycin
group and 24% (n=15) in Ceftriaxone group gave similar history.
In about 12.7% of the total cases there was history of typhoid fever
in the neighborhood which was equally distributed (13%) in both groups.
In 14.3% (n=18) of cases, the mother, who used to cook food for
the family, had suffered from typhoid fever in the past. In about 18%
(n=11) of the cases in the Azithromycin group and 11% (n=7) cases in the
Ceftriaxone group, the child’s mother had past history of typhoid fever. It
was also observed that 12% (n=15) of the total cases had suffered from
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typhoid fever in the past which was equally distributed in both the groups
(11%).
Among the study group, 13.5% (n=17) of vaccinated cases had
developed typhoid, of which 14% (n=9) cases came under Azithromycin
group and 13% (n=8) cases under Ceftriaxone group. Vaccine efficacy
[calculated by using the formula: {(incidence among unimmunized –
incidence among immunized)/incidence among unimmunized} X 100],
was observed to be 84.4%.
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Table 1: Epidemiological factors
FACTORS
Azithromycin Ceftriaxone
N % N %
Typhoid in other family
members
16 25% 15 24%
Typhoid in neighborhood 8 13% 8 13%
Source of
drinking water
mineral water 24 38% 18 29%
metro water
39 62% 45 71%
Boiled water use 15 24% 9 14%
Sanitary latrine common 27 43% 27 43%
separate 36 57% 36 57%
Typhoid vaccination 9 14% 8 13%
Eating from vendors 29 46% 27 43%
Past history of typhoid in
mother
11 18% 7 11%
Past history of typhoid in child 7 11% 7 11%
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Source of drinking water was metro water and mineral water cans
in 66.7% (n=84) cases and 33.3% (n=42) cases respectively. About 38%
(n=24) cases in Azithromycin group and 29% (n=18) in ceftriaxone group
used mineral water for drinking purpose, remaining 62% (n=39) and 71%
(n=45) cases used metro water, respectively. Only 19% (n=24) of the
total cases, 24% (n=15) cases in the Azithromycin group and 14% (n=9)
cases in the Ceftriaxone group consumed water after boiling and cooling.
Sharing toilets with other neighborhood families was observed in
42.9%  (n=54)  of  total  cases  and  in  equal  proportion  of  cases  in  both
groups (43%).
About 44.44% (n=56) cases gave history of eating ice creams,
chats and other junk food from vendors, out of which 46% (n=29) cases
were in Azithromycin group and 43% (n=27) cases in Ceftriaxone group.
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Symptomatology:
In the total study population, associated symptoms in decreasing
order of frequency were vomiting (54.8%), anorexia (46%), diarrhea
(40.5%),abdominal pain (31.7%), cough (25.4%),headache (19%),
myalgia (14.3%), loss of weight (5.6%) and constipation (4.8%),
The predominant symptom associated was vomiting (54%, n=34)
followed by anorexia (51%, n=32) and diarrhea (38%, n=24) in
Azithromycin group, where as in the Ceftriaxone group, anorexia (57%,
n=36) was the most common symptom associated, followed by vomiting
(56%, n=35) and diarrhea (43%, n=27).
Abdominal pain was seen more commonly in the Ceftriaxone
group (37%, n=23) when compared to other treatment group (27%,
n=17). But cough was more common in the Azithromycin group     (29%,
n=18) when compared to Ceftriaxone group (22%, n=14).
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Figure 6: Symptomatology (Azithromycin vs Ceftriaxone)
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Table 2: Symptomatology
SYMPTOM
Azithromycin Ceftriaxone
N = 63 N = 63
Chills and rigors 28 28
Headache 11 13
Myalgia 10 8
Anorexia 32 36
Weight loss 4 3
Vomiting 34 35
Diarrhea 24 27
Constipation 4 2
Abdominal pain 17 23
Abdominal distension 4 4
Cough 18 14
Pretreatment antibiotic
use 14 20
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Clinical signs:
On examination, the predominant sign observed in the study
population was hepatomegaly seen in 92.9% (n=117) cases, followed by
coated tongue, glossitis and cheilitis in 67.5% (n=85) cases,
splenomegaly in 57.1% (n=72) cases and toxemia in 55.6% (n=70) cases.
Other signs observed, in decreasing order of frequency were pallor
(52.4%, n=66), abdominal tenderness (19%, n=24), lymphadenopathy
(14.3%, n=18), abdominal distension (11.1%, n=14) and rose spots
(0.8%, n=1). It was the cervical group of lymph nodes which were
predominantly enlarged.
The most common sign elicited in both the groups was
hepatomegaly, seen in 94% (n=59) and 92% (n=58) cases in
Azithromycin and Ceftriaxone group respectively followed by coated
tongue, glossitis and cheilitis in 68% (n=43) cases in Azithromycin group
and 67% (n=42) cases in Ceftriaxone group. Splenomegaly was seen in
equal proportions in both the groups in about 57% (n=36) cases.
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Figure 7: Clinical signs (Azithromycin vs Ceftriaxone)
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Table 3: Clinical Signs in the study group
SIGN
Azithromycin Ceftriaxone
N = 63 N = 63
Febrile 63 63
Toxemia 34 36
Coated tongue, glossitis,
cheilitis
43 42
Pallor 31 35
Rose spots 0 1
Lymphadenopathy 10 8
Abdominal distension 7 7
Abdominal tenderness 9 15
Hepatomegaly 59 58
Splenomegaly 36 36
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Other clinical signs elicited in order of decreasing frequency were
toxemia (54%), pallor (49%), lymphadenopathy (16%) and tender
abdomen (14%) in Azithromycin group whereas in the Ceftriaxone group
it  was  toxemia  (57%),  pallor  (56%),  tender  abdomen  (24%)  and
lymphadenopathy (13%). Abdominal distension was seen in equal
proportions in both the groups in about 11% (n=7) of the cases. Rose
spots  was  seen  in  only  2%  (n=1)  of  cases  in  Ceftriaxone  group  while
none in the Azithromycin group had rose spots.
Investigations:
Complete Blood Count:
Total leucocyte count was normal in 85% (n=107) cases, with
leukocytosis in 14.3% (n=18) cases and leucopenia in only 0.8% (n=1)
cases.
The  mean  values  and  SD  of  hemoglobin,  total  WBC  count  with
differentials and platelet count in both the treatment groups is listed in
Table 7.
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Table 4: Complete blood count profile
Parameter
Azithromycin Ceftriaxone
Mean SD Mean SD
Hb 10.88 1.10 10.79 1.17
TLC 7857.14 3363.45 7850.79 2997.20
Neutrophils 52.93 11.72 53.61 13.38
Lymphocytes 37.35 10.15 37.19 11.59
Monocytes 9.16 4.88 8.36 3.50
Eosinophils 0.57 1.02 0.48 1.09
Basophils 0.45 0.35 0.46 0.37
Platelets 2.44 0.94 2.17 0.71
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It was observed that leukocytosis (TLC>11,000/dl) was seen in
equal proportions (17.5%, n=8) in both groups and leucopenia
(TLC<4000/dl) was seen in only 1.6% (n=1) of cases in Ceftriaxone
group and none in Azithromycin group. Thrombocytosis (platelet count
>5L/dl) was seen in only 1.6% (n=1) of cases in Azithromycin group and
none in Ceftriaxone group. Thrombocytopenia (platelet count <1.5L/dl)
was observed in 17.5% (n=11) cases in Azithromycin group and 23.8%
(n=15) cases in Ceftriaxone group.
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Figure 8: CBC profile (Azithromycin vs Ceftriaxone)
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CONFIRMATORY TESTS:
Flowchart 1: Confirmatory test positivity (Azithromycin vs
Ceftriaxone)
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Figure 9: Diagnostic test positivity (Azithromycin vs Ceftriaxone)
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Type of Organism Grown:
Among the culture positive cases, 96% cases in both groups grew
Salmonella typhi and remaining 4% grew Salmonella paratyphi A.
Figure 10: Type of organism grown in culture (Azithromycin vs
Ceftriaxone)
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Drug sensitivity and resistance pattern:
Resistance to Nalidixic acid was seen in 42.8% (n=21) of cases in
Azithromycin group and 11.5% (n=6) cases in the Ceftriaxone group.
Multi  drug  resistant  Salmonella  typhi  was  grown  in  6%  (n=3)  cases  in
Azithromycin group and in 5.8% (n=3) cases in Ceftriaxone group.
Ceftriaxone resistance was observed in 18.4% (n=9) cases in
Azithromycin group and in 7.7% (n=4) cases in Ceftriaxone group.
TABLE 5: MDRST, NARST & Ceftriaxone resistance
Drug resistance
Azithromycin Ceftriaxone
N N
NARST 21 6
MDRST 3 3
Ceftriaxone resistant 9 4
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Figure 11: Drug resistance pattern (Azithromycin vs Ceftriaxone)
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Figure 12: MDRST, NARST and Ceftriaxone resistance (S.typhi vs
S.paratyphi)
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Table 6: MDRST, NARST & Ceftriaxone resistance
Drug resistance S.typhi S.paratyphi
(MDRST (N=6) 6 0
NARST (N=27) 26 1
Ceftriaxone resistance
(N=13) 13 0
Time taken for diagnosis:
       The mean time taken for arriving at the diagnosis in Azithromycin
group was 2.89±1.357days and in the Ceftriaxone group was 2.89±1.259
days.
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Table 7: Outcome measures - Mean, SD & SE of mean
Descriptive Statistics
Groups N Mean
Std.
Deviation
Std.
Error
Mean
Duration at
diagnosis
Azithromycin 63 2.89 1.357 0.171
Ceftriaxone 63 2.89 1.259 0.159
Defervescence
Azithromycin 63 3.68 2.109 0.266
Ceftriaxone 63 4.08 1.903 0.24
Duration of
hospital stay
Azithromycin 63 7.35 2.604 0.328
Ceftriaxone 63 9.44 1.974 0.249
Relapse
Azithromycin 63 0.79 0.408 0.051
Ceftriaxone 63 0.87 0.421 0.053
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Fever clearance time:
The mean fever clearance time in Azithromycin group was
3.68±2.109 days     (SE 0.266 and 95% CI) and in Ceftriaxone group was
4.08±1.903 days (SE 0.24 and 95% CI). The p value obtained on
comparing the two groups with respect to fever clearance is 0.27.
Figure 13: Mean fever clearance time
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Cross over and treatment failure:
        About 4.8% (n=3) cases in Azithromycin group failed to respond to
the drug by 7days and hence crossed over to Ceftriaxone group. 6.3%
(n=4) cases had delayed response to intra venous Ceftriaxone requiring
continuation of the drug for more than 7days till 24-48hrs of
defervescence.
Duration of Hospital stay:
        The mean duration of hospital stay in the Azithromycin group
was7.35±2.604 days (SE 0.328) and in the Ceftriaxone group was
9.44±0.249days (SE 0.249). The p value obtained on comparing the two
groups with respect to duration of hospital stay was 0.0001 which is
highly significant.
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Figure 14: Mean duration of hospital stay
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Relapse:
During thirty day follow up, 3.2% (n=2) cases in the Ceftriaxone
group had relapsed but there was no relapse in the Azithromycin group.
The p value obtained on comparing both the groups with respect to
relapse is 0.285 which is statistically insignificant.
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Table 8: Independent t test for outcome measures
Independent Samples Test
Equal
variances
assumed
Levene's Test for Equality of Variances
t-test for Equality of
Means
95% C I of the
Difference
F
test
value
p value t testvalue Df p value Mean
Difference
Std. Error
Difference Lower Upper
Duration
at diagnosis
1.879 0.173 (NS) 0 124 1 (NS) 0.000 0.233 -0.462 0.462
Defervescence 0.798 0.373 (NS) -1.109 124 0.27 (NS) -0.397 0.358 -1.105 0.312
Duration
Of hospital
stay
1.26 0.264 (NS) -5.09 124 0.0001*** -2.095 0.412 -2.91 -1.28
Relapse 1.022 0.314 (NS) -1.075 124 0.285(NS) -0.079 0.074 -0.226 0.067
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Analysis of Primary Objective:
On applying Null hypothesis that oral Azithromycin is as effective
as intra venous Ceftriaxone in the management of uncomplicated Enteric
fever, p value obtained with respect to fever defervescence was 0.27.
Hence Null hypothesis not rejected. It means that in 27% of the study
group, Azithromycin is as effective as Ceftriaxone. But in the remaining
73%, Azithromycin is not as effective as Ceftriaxone.
On calculating the mean difference for fever clearance in both the
groups it was -0.397 i.e. the time taken for fever clearance in
Azithromycin group was lesser than that in the other group. It implies that
Oral Azithromycin may be more effective than intra venous Ceftriaxone
(A>C). But because the study sample was small, this inference is not
statistically significant.
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Flow chart 2: Patient enrollment and follow up
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DISCUSSION
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DISCUSSION
Typhoid fever accounts for significant morbidity among children in
our country. It is not just the morbidity of the illness alone but also the
socioeconomic burden which has important implications in the effective
management of the disease. Financial constraints are encountered, not
only by the expenses of hospital admission for IV antibiotics but also by
the loss of wages of working parents. The recent upsurge in MDRST and
NARST is a rising concern to the managing physician and has prompted
further clinical trials to search for newer, cheaper and orally available
drugs.
In our study an attempt was made to test  the efficacy of  an orally
available drug namely Azithromycin in treating enteric fever as compared
to the classically administered injectable Ceftriaxone. Besides we also
studied the clinical, laboratory and epidemiological profile of these cases
with  a  view  to  find  out  whether  any  of  these  factors  could  predict  the
occurrence of the disease or make a difference to the outcome after
treatment. A total of 126 children with uncomplicated enteric fever were
grouped into two groups; one received Azithromycin, the other
Ceftriaxone. Both groups were compared with regard to efficacy.
97
The  mean  age  of  the  participants  in  our  study  group  was  7years,
with 44.4% in the age group of 2-6years and 55.6% between 7-12years
(Figures 1 & 2). The rising typhoid incidence in younger age noted in our
study is related to improper sanitation and due to the fact that younger
children are unaware of heath hygiene. The male: female ratio was
1.29:1in our study (Figures 3 & 4), which was similar to that seen in the
study by Ganesh et al. 14 The predominant clinical profile (Table 2 & 3;
Figures  5,  6  &  7)  observed  in  our  study  was  fever  associated  with
vomiting, anorexia, diarrhea and hepatosplenomegaly, which was similar
to that reported in other studies. 14, 28, 29
Mary Mallon, a cook, was described as ‘the most dangerous lady of
the United States’, for the epidemics of typhoid she had caused as a
chronic carrier. In about 14.3% of the cases in our study, the mother who
used to cook food for the family had suffered from typhoid fever in the
past (Table 1). History of typhoid fever in other family members was
seen in 24.6% of cases as compared to 6% observed by Ram et al.18 This
fact calls for a strong recommendation for testing carrier state in adult
typhoid patients following cure. 2, 18
They also observed that almost 90% of the cases in their study used
unboiled drinking water as against 81% cases in our study, thus
highlighting the need for boiling water as part of food safety. 18
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They found a statistically significant association between use of
sanitary latrines for defecation and the occurrence of typhoid fever. They
had concluded that the use of sanitary latrines was protective against
acquiring the infection. In our study 100% of the cases used sanitary
latrine for defecation and about 43% of the cases shared toilet facilities
with other families, thereby compromising health hygiene.18
Though enteric fever is classical known to have leucopenia, in our
study 85% cases had normal total count with leucopenia observed only in
one case and leukocytosis in 14.3% (n=18) cases (Figure 8). This was in
agreement with Ganesh et al14  study, though they had observed a lesser
percentage of cases with leukocytosis.
The global increase in the emergence of resistant strains among
salmonella typhi is well documented. In our study NARST accounted for
21.4%, MDRST for 4.8% and Ceftriaxone resistance in10.3% of cases.
Out of the 21.4% cases of NARST, 0.8% of S.paratyphi and 20.6% of
S.typhi were Nalidixic acid resistant strains (Table 5 & 6; Figure 11 &
12).  None  of  the  paratyphi  strains  were  MDRST  nor  resistant  to
Ceftriaxone. The occurrence of resistance was much lower when
compared with Walia et al28 study, wherein they have noted 76.7% and
74.3% cases of NARST in the S.paratyphi and S.typhi groups
respectively. MDRST observed in their study was 19.7% cases in S.typhi
group and none in paratyphi group. They had no cases of Ceftriaxone
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resistance  in  their  study.  Our  hospital  caters  to  the  ESI  beneficiaries  for
whom, under the social security scheme, holistic medical care is given
with minimum individual contribution. Hence the parents directly come
to us seeking medical attention for febrile illness in their children. Thus
protection is offered against indiscriminate antibiotic use since drugs are
started only after some confirmatory evidence, except in emergencies. A
much lower percentage of MDRST in our series is an indirect proof
against antibiotic abuse. The emerging drug resistance to Ceftriaxone
seen in our series is probably related to the fact that before undertaking
this study Ceftriaxone was given being used as the sole drug for all cases
of proved enteric fever.
In their retrospective analysis of cases spread over 2 years, Ganesh
et al14 observed that NARST had increased from 56% in the first year to
73% in the second year, probably again related to the surging antibiotic
abuse.
Comparison of relative efficacy of Azithromycin and Ceftriaxone
was done in terms of fever defervescence, duration of hospital stay and
relapse (Table 7 & 8; Figures 13 & 14). The mean fever clearance time in
Azithromycin group was 3.68±2.109 days and in Ceftriaxone group was
4.08±1.903 days. The earlier fever defervescence seen with Azithromycin
marks its potential as a promising oral alternative. This inference though
statistically not significant, because of the small number, paves the way
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for larger studies in future. The difference in defervescence pattern with
the use of both the drugs in our study is however contrary to that
observed by Frenck et al27 wherein they had observed early defervescence
with Ceftriaxone rather than with Azithromycin. The emerging resistance
over the last 10 years has probably caused the change in fever
defervescence pattern with the usage of both the drugs.
Gupta  et  al29 had noted a fever clearance time of 4.3days with
Ceftriaxone. In other noncomparative studies where only Azithromycin
was used, such as those done by Anju et al20 and Hussain et al22, the mean
duration of defervescence was 3.45±1.92 days and 4days respectively.
These observations concurred with our findings.
The mean duration of hospital stay in the Azithromycin group was
7.35±2.604 days and in the Ceftriaxone group were 9.44±0.249 days. The
p value obtained on comparing the two groups with respect to duration of
hospital stay was 0.0001 which was highly significant. Implying that oral
Azithromycin significantly reduces the duration of hospital stay when
compared to intra venous Ceftriaxone. Thus with the use of
Azithromycin, there is a convenience of early discharge soon after fever
and toxemia clears as the course can be completed even at home. In
nontoxic cases there remains an option of using the drug even on
outpatient basis thus making it a better alternative.
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In enteric fever, there always remains a potential risk of relapse
following even effective treatment. About 3.2% (n=2) cases treated with
Ceftriaxone relapsed within 4 weeks of treatment, which was lesser when
compared to that observed by Bhutta et al30, Parry et al24 and Dutta et al31
(5-10%) and Frenck et al27 (19%) in their studies. Azithromycin group
did  not  have  any  relapse,  which  was  similar  to  that  seen  in  studies  by
Frenck et al27,  Anju  et  al20 and  Hussain  et  al.22 Use of Azithromycin
seems to have some protection against relapses which can be considered
as a definite advantage.
Out of the four cases that had delayed response to intra venous
Ceftriaxone, one was resistant to Ceftriaxone but ultimately responded.
Two cases relapsed and one case neither had resistance to Ceftriaxone nor
relapsed.
The dreaded complication of asymptomatic carrier state following
enteric fever is more of adult concern and children are sort of protected
from this state. This is also seen in our study wherein none of the children
in both the groups had a positive fecal culture during the 4 weeks follow
up, which was similar to the observation made by Frenck et al.27
Vaccine efficacy in our series was 84.4%, as against 32% observed
by Ganesh et al in their study.14 Since preliminary analysis showed that
vaccine administration offered a significant protection against the disease,
we in our hospital have started this immunization for pediatric patients on
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a trial basis and are attempting to compare the incidence of enteric fever
in the next few years as compared to the pre vaccination era.
Thus in our study oral Azithromycin was found to be as effective
as intravenous Ceftriaxone in terms of fever defervescence, duration of
hospital stay and prevention of relapse though larger studies are required
for validating. Being an oral drug, it markedly reduces the admission
expenditure as well as prevents loss of wages for working parents thus
reducing the overall socio economic burden.
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CONCLUSION
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CONCLUSION
1. With regards to the primary objective, we found in our study that
Oral Azithromycin is as effective as intravenous Ceftriaxone in
treating typhoid fever. Though the time taken for fever clearance
was not statistically significant between the two treatment groups,
Azithromycin has a slightly earlier fever clearance than
Ceftriaxone with no relapse.
2. Being  an  oral  drug,  it  does  significantly  reduce  the  duration  of
hospitalization, thereby reducing the loss of working days for the
child’s parents and finally reducing the socioeconomic burden to
some extent.
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LIMITATIONS
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LIMITATIONS
1. The sample size in our study was small. Hence further studies are
needed to validate these results.
2. Demonstration of microbiological response or failure, by repeating
culture at 1 week could not be done due to resource constraints.
3. The relative efficacy of the drugs was determined purely on clinical
grounds. Minimum inhibitory concentrations of the drugs could not
be estimated due to resource constraints.
4. There was no blinding in our study.
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RECOMMENDATIONS
108
RECOMMENDATIONS
1. Oral Azithromycin can be used in place of intravenous Ceftriaxone
in the management of uncomplicated Enteric fever to reduce time
taken for fever defervescence, duration of hospital stay and to
prevent relapse.
2. Management of every case of Enteric fever should be holistic,
addressing not only the acute illness, but also the risk factors by
providing effective health education and promoting environmental
hygiene.
3. Adult households must be screened for chronic carrier state.
4. Prevention is always better than cure; hence vaccination against
typhoid fever must be propagated and practiced effectively to
reduce the National and Global burden of the disease.
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surya 11 M 10 intermittent A A A A A P A P A A A A A A Y A P P A A A A A P P A A N N Metro water N Separate N Y N N azithromycin 7days 2days 5days 2days 11.3 8600 51.4 38.6 9.2 0.1 0.7 3.3 >1:160 >1:160 S.typhi S S S S S S sterile N N N
Chandralekha 2 F 5 intermittent P A A A A P A A P A A A A A N P P P P A A A A A P P A N N Metro water N Separate N N N N azithromycin 7days 5days 10days 5days 10 13900 38 50 11 0.3 0.8 2.36 0 0 S.typhi R R R R S R sterile Y Y Y
Abhinaya 10 F 9 intermittent A A A A A A A P P A P A A A N P P P A A A A A A P P A N Y Metro water N Separate N N N N azithromycin 7days 2days 6days 2days 11.6 7400 54 40 3 3 0 2.57 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
Sajani 2 F 7 intermittent A A A A A A P P A P A A A A N P P P P A A A P A P P A N N Metro water N Separate N N N N azithromycin 7days 5days 7days 2days 9.5 8400 62 31 6 0.7 0.7 1.4 >1:160 >1:160 S.typhi S S S S S S sterile N N N
Pawan kumar 2 M 6 intermittent A A A A A P A A A A A A A A N P P P P A A A A A P A A N N Metro water N Separate N N N N azithromycin 7days 2days 6days 2days 10 14200 46.5 46 6.5 0.2 0.8 1.5 >1:160 >1:160 S.typhi S S S S S S sterile N N N
Adhira krishnan 8 F 7 intermittent P A A A A A A A A A P A A A N P P P A A A A A A P A A N N Metro water N Separate N N N N azithromycin 7days 3days 6days 1day 11 7600 50 40 8 1 0.9 1.3 >1:160 >1:160 S.typhi S S S S S S sterile N N N
Narendar 5 M 5 intermittent A A A A A A A A A A A A A A N A P P P A A P A A P P A N N Mineral water N Separate Y N N N azithromycin 7days 6days 10days 2days 10.6 4300 51.7 36.1 11.7 0.1 0.4 2.18 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
sabir basha 10 M 9 intermittent P A A A A P A P A A P A A A N P P P A A A A A A P P A Y N Metro water N common N Y Y Y azithromycin 7days 5days 7days 1day 12 6100 62 25.1 12.3 0.1 0.5 2.49 >1:160 >1:160 S.typhi S S S S S S sterile N N N
vijaya kumar 6 M 15 intermittent P A A A A P A A A A P A P A Y A P A P A A P A A P A A N N Metro water N common N N Y N azithromycin 7days 2days 7days 4days 10.2 4800 52.6 39.6 7 0.1 0.8 2.44 >1:160 >1:160 S.typhi S S S S S S sterile N N N
jayashree 7 F 7 intermittent P A A A A A A P A A P A P A N A P A A A A P A P P P A N N Mineral water N common N N N N azithromycin 7days 5days 10days 3days 11.6 12000 54.9 36.4 8.2 0.2 0.3 1.85 >1:160 >1:160 sterile 0 0 0 0 0 0 sterile 0 0 0
vignesh 4 M 4 intermittent P A A A A A A P P A A P A A N P P P P A A P A A P A A N N Metro water Y Separate N Y N Nazithromycin for 5days and ceftriaxone for 10days15days 12days 17days 6days 8.1 7500 39.7 44.8 14.9 0 0.6 2.27 >1:160 >1:160 S.typhi S S S S SModerately sensitivest rile N N N
sabari 4 M 4 intermittent P A A A A P P A A A A A A A N A P A P A A A A P P P A Y N Metro water N Separate N N N N azithromycin 7days 2days 7days 4days 10.9 5900 36 51.8 9.8 1.5 0.9 2.86 0 0 S.typhi S S S S S S sterile N N N
praveen kumar 7 M 10 intermittent P P A A A P A A A A A A A A N A P P P A A A A A P P A N N Metro water Y common N N N N azithromycin 7days 2days 5days 2days 11 6200 42 44.2 10.7 3 0.1 2.36 >1:160 >1:80 S.typhi S S S S S S sterile N N N
Rohith 6 M 7 intermittent P P A A A A A A A A A A P A Y A P A A A A A A A P A A Y N Metro water N Separate N Y Y N azithromycin 7days 2days 5days 2days 11.1 6500 36.4 49.1 10.9 2.8 0.8 3.15 0 0 S.typhi S S S S S S sterile N N N
Kabilan 10 M 10 intermittent P P P A A A P A P A P A A A Y P P P A A A A A A P P A N N Mineral water N Separate N N N N azithromycin 7days 2days 2days 5days 11.9 5900 50.4 41.2 7.9 0.1 0.4 2.09 0 0 S.typhi S S S S S S sterile N N N
manimegalai 12 F 7 intermittent P P P A P A P A A A A P A N A P A A A A A A A P A A Y N Metro water Y common N Y N Y azithromycin 7days 4days 7days 2days 13 6600 49 41.5 9.2 0.3 0.1 2.02 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
subburam 8 M 5 intermittent P A A A A A A A A A A A A A N A P A A A A P A A P A A N N Metro water N common N Y N N azithromycin 7days 2days 5days 2days 12.5 4400 60.2 29.4 9.4 0.2 0.8 2.22 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
sanjay 9 M 8 intermittent P A A A A P A P P A A A A A N P P P A A A A A A P A A N N Metro water Y Separate N N N N azithromycin 7days 2days 7days 3days 10.8 8400 58 32.6 9.4 0 0 2.6 >1:160 >1:80 S.typhi S S S R S R sterile Y N Y
sofia rani 4 F 10 intermittent A A A A A A A A A A A A A A Y A P P P A A A A A P A A N N Mineral water N common N Y N N azithromycin 6days 8days 15days 2days 10.8 14200 50.6 38.2 38.2 0.1 0.4 4.69 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Nithyashree 11 F 14 intermittent P A A A A P A A A A A A A A N P P P A A A A A A P A A N N Metro water N common N Y N N azithromycin 7days 2days 4days 1day 11.1 6400 54.7 32.2 10.5 1.7 0.9 3.43 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Karthik 11 M 7 intermittent A A A A A A A P P A P A A A N A P P A A A A A A P A A N N Mineral water N Separate N N N N azithromycin 7days 2days 7days 4days 11.5 8700 55.1 34.1 10.4 0.1 0.3 3.17 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Manoranjitham 3 F 6 intermittent A A A A A P A A A A P A A A N P P P A A A A A A P A A Y N Mineral water N common N N N N azithromycin 7days 4days 10days 5days 11.1 6900 36 54.8 8.4 0.1 0.7 3 <1:40 <1:30 S.typhi S S S S S S sterile N N N
prashanth 11 M 17 intermittent A A A A A P P P A A A A P A Y P P P A A A A A A P A A N N Metro water Y Separate N N Y N azithromycin 7days 3days 5days 1day 11.6 13300 52.5 40.2 6.7 0.1 0.5 2.31 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Karthiga 6 F 10 intermittent A A A A A A A A A A A A A A N A P A A A A A A A P P A Y N Mineral water N common Y N N Y azithromycin 7days 5days 6days 1day 11.6 9200 44.3 43.1 12 0.2 0.4 2.12 0 0 S.typhi S S S S S S sterile N N N
Balavignesh 8 M 7 intermittent A A P A A A A A A A A A P A N A P P P A A A A A P P A N N Metro water N common N N N N azithromycin 7days 2days 7days 5days 10.1 8400 51.5 39.9 6.9 1.2 0.5 2.81 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Amith kumar 4 M 8 intermittent P A A A A A A A A P A A P A N P P P A A A A A A P P A N Y Mineral water N common N Y N N azithromycin 7days 3days 7days 4days 8.3 7700 51 44.3 4.7 0 0 2.57 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
rakesh 6 M 7 intermittent P A P A A P A P A P A A P A N P P P A A A A A A P P A N Y Metro water N common N N N N azithromycin 7days 6days 7days 2days 11.1 10200 51.4 40.8 6.6 0.1 1.1 2.28 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
yuvashree 7 F 5 intermittent P A A A A P A P A A A A P A N P P P A A A A A A P p A N N Metro water N common N Y Y N azithromycin 7days 3days 8days 4days 11.3 7300 52.1 34 11.2 1.7 1 2.1 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
john 4 M 7 intermittent A A A A A A A A A A P A A A N P P P P A A A A A P P A Y N Mineral water N Separate N N N N azithromycin 7days 7days 9days 1day 10.3 9300 44.5 46.4 9.1 0 0 3.07 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
renuka 9 F 8 intermittent P A A A A P A P P A A A A A N P P P P A A P A A P P A Y N Mineral water N Separate Y Y N N azithromycin 7days 2days 6days 3days 11 8500 60 30 9.4 0.1 0.2 2.65 0 0 S.typhi S S S R S R sterile Y N Y
dhanesh 11 M 5 remittent A A A A A P A P P A A A P A N P P P A A A A A A P A A Y N Mineral water N Separate N Y N N azithromycin 7days 6days 9days 3days 12.2 7300 44.6 42.4 8.8 3.3 0.6 4.9 <1:20 <1:20 S.typhi R R R R S S sterile Y Y N
yuvraj 8 M 3 intermittent A A A A A P A P P A A A P A N A P P P A A A A A P P A N N Metro water N Separate N Y N N azithromycin 7days 3days 8days 4days 10.6 9400 31 53.1 10.3 4.8 0.8 3.9 0 0 S.typhi S S S R S R sterile Y N Y
mahendran 11 M 10 intermittent P A P A A P A P P A A A A A Y P P P P A A A A A P P A N N Metro water N common N Y N N azithromycin 7days 4days 10days 5days 11.4 5200 60 30 9 0.1 0.1 1.45 <1:20 <1:20 S.typhi S S S R S S sterile Y N N
hemavathi 7 F 6 intermittent P A P A A P A A A A A A P A N P P P P A A A P A P P A N N Metro water Y Separate N Y N N azithromycin 7days 3days 7days 2days 11.4 5900 50 35 14 2.5 0.1 2.5 <1:20 <1:20 S.typhi S S S R S S sterile Y N N
priscilla 6 F 8 intermittent A A A A A P A P P A A A A A N A P A P A A A A A P A A N N Mineral water Y Separate Y Y Y N azithromycin 7days 4days 8days 3days 11.6 6300 56.9 35.9 6.2 0.1 0.9 2 0 0 S.typhi S S S R S R sterile Y N Y
sadik 8 M 7 intermittent P A P A A P A A A A A A P A Y A P A P A A P A P P P A N N Metro water N common N Y N Y azithromycin 7days 6days 11days 4days 11.4 4200 65.4 27 7.6 0 0 2.25 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
dhanyashri 11 F 7 intermittent A A A A A P A A A A A A A A N A P A P A A A A A P A A N N Mineral water N Separate N N N N azithromycin 7days 2days 4days 1day 10 25100 60.2 23.9 15.1 0.1 0.7 4.33 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
Gayathri devi 10 F 7 intermittent P P P A A A A A A A A A P A Y P P A P A A A A A A A A N Y Mineral water N Separate Y Y N N azithromycin 7days 3days 8days 4days 9.6 4200 35.9 50.9 12.4 0.1 0.7 1.64 >1:40 <1:20 S.typhi S S S R S S sterile Y N N
ramakrishnan 7 M 7 intermittent A A A A A A A A A A A A P A N A P P P A A P A A P P A N N Metro water Y Separate N N N N azithromycin 7days 2days 4days 1day 9.8 7900 44.9 45.8 9.3 0 0 2.17 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
visakan 12 M 7 intermittent P P A A A A A P A A A P A A N A P A A A A A A P P A A Y N Mineral water N common N Y N N azithromycin 7days 2days 8days 4days 14.2 5600 55.3 30.2 13.9 0 0.6 2.68 <1:20 <1:20 S.paratyphi A S S S S moderate sensitiveS sterile N N N
Roseline 11 F 7 intermittent A P A A A P A A A P A A A A N A P P A A A A A A P P A N Y Metro water N common N Y N N azithromycin 7days 2days 4days 1day 11.6 8400 53.5 32.9 11 2.4 0.2 3.56 0 0 S.typhi S S S S SModerately sensitivest rile N N N
Dashwanth 4 M 5 intermittent A P A A A A A P A A A A P A Y A P P P A A A A A A A A Y Y Mineral water N Separate N Y Y N azithromycin 7days 2days 5days 2days 8.8 5200 54.1 40.1 5.8 0 0 1.9 >1:160 >1:160 S.typhi S S S S S S sterile N N N
harikrishnan 8 M 4 intermittent A A A A A A A A P A P A P A N A P A A A A A A A P P A Y N Metro water N Separate N N N Y azithromycin 7days 2days 7days 4days 11.3 5700 61.8 32.4 5.8 0 0 1.36 0 0 S.typhi S S S S S S sterile N N N
deepika 11 F 15 intermittent P A A A A A A P A A P A A A N A P P P A A A A A P P A N N Metro water N Separate N Y N N azithromycin 7days 5days 7days 1day 10.3 8000 57.4 33.6 8.1 0.1 0.8 2.24 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
devanandhan 10 M 3 intermittent P P A A A A A P P A A A A A N A P A A A A A A A A A A N N Metro water Y common N Y Y N azithromycin 7days 4days 9days 4days 11.2 5300 74.9 21.1 4 0 0 1.86 0 0 S.paratyphi A S S S R S S sterile Y N N
dharanitharan 6 M 7 intermittent P A P A A P A P A A A A A A N P P P P A A A A A P P A N Y Mineral water Y common N N N N azithromycin 7days 4days 9days 2days 9.9 7000 68.4 27.3 4.3 0 0 3.44 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
Abhinaya 8 F 10 intermittent P A A A A A A A P A A P A A N A P P A A A P P A P A A N N Mineral water Y Separate Y Y Y N azithromycin 7days 3days 7days 4days 12.2 6600 51.1 37.3 10.8 0.3 0.5 2.37 0 0 S.typhi S R S S S S sterile N N N
emancy 2 F 13 intermittent A A A A A A A P P A A A A A Y A P A P A A A P A P P A Y Y Mineral water Y Separate N N N N azithromycin 7days 2days 7days 3days 9.4 12200 40.6 48.2 10.1 0.6 0.5 6.19 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
gomathi 9 F 4 intermittent A A A A A A A P P A P A A A N P P A A A A A A P P P A Y N mineral water N Separate Y Y N N azithromycin 7days 5days 8days 3days 11 4200 52 46.5 2 0.1 0.1 1.5 0 0 S.typhi R R R S S S sterile N Y N
hemavathi 8 F 8 intermittent A A A A A P A P A A A A A A Y P P P A A A P A A P P A N N metro water Y Separate N N Y N azithromycin 7days 4days 9days 5days 10.9 7400 68.7 23.4 7.1 0.1 0.7 2.03 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
mahesh 2 M 4 intermittent A A A A A P A P P A A A A A N P P P P A A A A A P A A N N metro water Y Separate N N N N azithromycin 7days 3days 5days 2days 9.5 6100 58.3 36.7 5 0 0 1.5 0 0 S.typhi S S S S S S sterile N N N
ramesh 2 M 3 intermittent A A A A A A A A A A A A A A Y A P A P A A A A A P P A N N mineral water N common N N Y N azithromycin 7days 3days 7days 4days 10.5 9300 29 58.8 12.2 0.1 0.1 1.33 0 0 S.typhi S S S S S S sterile N N N
dharun 8 M 8 intermittent P A A A A A A A P A A A A A N P P P A A A A A A P A A N N metro water N Separate N Y N N azithromycin 7days 3days 7days 4days 12.9 6000 60 35.2 4.3 0.1 0.4 1.2 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
dhanesh 10 M 3 intermittent A P A A A A A P P A P A A A N P P P A A A A A A A A A N N mineral water N common N N N N azithromycin 7days 4days 8days 4days 11 5400 75.7 15.7 8.3 0.1 0.2 2.14 0 0 S.typhi S S S S S S sterile N N N
sarath 10 M 7 intermittent A P P A A A A P A A A A A A N P P P A A A A A A P P A N N metro water N Separate N Y N N azithromycin 7days 3days 7days 3days 11.9 6700 72.6 19.7 7.1 0.1 0.5 2.63 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
devesh 9 F 7 intermittent A A A A A P A P P A P A A A N P P P A A A A P A P P A Y N metro water N common Y Y N N AXC 14days 12days 15days 3days 11.3 5000 80.9 15.5 2.8 0.5 0.3 65000 >1:160 >1:160 S.typhi S S S S S S S.typhi N N N
keerthi 12 F 7 intermittent A A A A A P A P P A P A P A N P P A A A A A A A P A A Y N metro water N common N Y N N azithromycin 7days 4days 7days 3days 11.6 4800 52.1 43 4.8 0 0.1 1.96 >1:160 >1:160 S.typhi S S S S S S sterile N N N
sameera banu 2 F 5 intermittent A A A A A A A P A A P P A A N P P P A A A A P P P P A N N mineral water N Separate N N N Y azithromycin 7days 2days 5days 2days 11.5 11300 63.4 28.9 7.2 0.1 0.4 2.47 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
krithi 6 F 8 intermittent A A A A A P A P P A A A A A Y P P P P A A A P A P P A N N metro water N Separate N N N N azithromycin 7days 5days 7days 2days 9.6 6300 49.6 36.7 11.9 0.5 1.3 1.93 >1:160 >1:40 sterile 0 0 0 0 0 0 0 0 0 0
ranjith 2 M 7 intermittent A A A A A P A A P A A A A A N A P A P A A A A A P P A N N metro water N Separate N N N N azithromycin 7days 4days 6days 2days 9.5 `12000 51.5 39.4 8 0.1 1 2.46 >1:160 >1:160 S.typhi S S S S S S sterile N N N
preethi 2 F 11 intermittent A A A A A A A P A A A A A A N P P P P A A A A A P p A N N metro water N common Y N N Y azithromycin 7days 2days 4days 1day 9.1 7100 25.9 61.6 11.6 0.2 0.7 2.36 >1:160 >1:160 S.typhi S S S S S S sterile N N N
vignesh 2 M 5 intermittent A A A A A P A A A A A A A A N A P A P A A A A A P A A N N metro water Y common N N N N azithromycin 7days 3days 7days 4days 10.6 9400 46.8 36.5 16 0.3 0.4 1.96 <1:20 <1:20 S.typhi S S S S S S sterile N N N
pranesh 12 M 7 intermittent A A A A A A A P P A P A A A N P P P P A A A A P P P A N N mineral water N common N N N N azithromycin 7days 4days 9days 5days 10.9 5700 83.9 13 3.1 0 0 1.5 0 0 S.typhi S S S S S S sterile N N N
ANNEXURE - IV
MASTER CHART
santhosh 5 M 15 intermittent P A A A A A A A A A A A A A Y P P P P A A A A A P P A N N metro water N common N Y N N ceftriaxone 7days 3days 8days 2days 9.6 8200 46.9 40.8 11.5 0 0.8 2.45 >1:160 >1:160 S.typhi S S S S S S sterile N N N
dinesh kumar 10 M 14 remittent P A A A A P A P A A P A P A N A P P A A A P A A P A A Y N metro water N Separate Y Y N Y ceftriaxone 7days 3days 8days 2days 11 8700 64 31.9 4.1 0 0 2.75 0 0 S.typhi S S S R S S sterile Y N N
kannimozhi 11 F 7 intermittent P P A A A A A A P A P A A A N A P A P A A A A A P P A N N metro water N common N Y Y N ceftriaxone 7days 3days 11days 5days 11.2 7600 60.7 30.7 8.1 0 0.5 2.43 >1:160 <1:20 S.typhi S S S S S S sterile N N N
kamalesh 6 M 10 intermittent A A P A A A A P P A A A A A N A P A P A A A A A A A A N N metro water N common N N N N ceftriaxone 7days 6days 11days 4days 12 6600 56.4 34.5 7.7 0.1 1.3 3.24 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
swarna kumar 11 M 7 intermittent P A A A A A A A A A A A P A N P P P A A A A A A P A A N Y mineral water N Separate Y N N N ceftriaxone 7days 5days 11days 3days 12.2 9100 51 37.2 11.2 0.1 0.3 2.28 <1:20 <1:20S. paratyphi A S S S S S S sterile N N N
madhumeena 2 F 7 intermittent A A A A A A A P P A A P A A N P P P P A A A P A P A A Y N metro water N Separate N N N N ceftriaxone 10days 7days 13days 3days 8.1 11600 37.1 50.6 12.3 0 0 1.1 0 0 S.typhi R R R S S R sterile N Y Y
shyam 6 M 8 intermittent A A A A A P A P P A P A A A Y P P P A A A P A P P P A N Y metro water N common N Y N N ceftriaxone 7days 5days 9days 2days 11.3 8200 45.9 42.8 9.2 1.5 0.6 3.44 >1:160 >1:160 S.typhi S S S S S S sterile N N N
Boni 9 M 7 intermittent P P A A A A A A P A A A A A N A P P A A A A A P P A A N Y mineral water N Separate N Y N N ceftriaxone 10days 6days 11days 3days 11.6 6500 64.7 30.3 5 0 0 2.06 >1:160 >1:160 S.typhi S S S S S S S.typhi N N N
hemalatha 9 F 4 intermittent A A A A A A A P P A P A A A N P P A A A A A A P P P A Y N mineral water N Separate Y Y N N ceftriaxone 7days 5days 10days 3days 11 4200 52 46.5 2 0.1 0.1 1.5 0 0 S.typhi R R R S S S sterile N Y N
gomathi 8 F 8 intermittent A A A A A P A P A A A A A A Y P P P A A A P A A P P A N N metro water Y Separate N N Y N ceftriaxone 7days 6days 15days 5days 10.9 7400 68.7 23.4 7.1 0.1 0.7 2.03 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
Madhesh 2 M 4 intermittent A A A A A P A P P A A A A A N P P P P A A A A A P A A N N metro water Y Separate N N N N ceftriaxone 7days 3days 7days 2days 9.5 6100 58.3 36.7 5 0 0 1.5 0 0 S.typhi S S S S S S sterile N N N
monish 2 M 3 intermittent A A A A A A A A A A A A A A Y A P A P A A A A A P P A N N mineral water N common N N Y N ceftriaxone 7days 3days 8days 4days 10.5 9300 29 58.8 12.2 0.1 0.1 1.33 0 0 S.typhi S S S S S S sterile N N N
dhanush 8 M 8 intermittent P A A A A A A A P A A A A A N P P P A A A A A A P A A N N metro water N Separate N Y N N ceftriaxone 7days 3days 8days 4days 12.9 6000 60 35.2 4.3 0.1 0.4 1.2 >1:160 >1:160 S.typhi S S S R S S sterile Y N N
david 10 M 3 intermittent A P A A A A A P P A P A A A N P P P A A A A A A A A A N N mineral water N common N N N N ceftriaxone 7days 4days 8days 4days 11 5400 75.7 15.7 8.3 0.1 0.2 2.14 0 0 S.typhi S S S S S S sterile N N N
saran kumar 10 M 7 intermittent A P P A A A A P A A A A A A N P P P A A A A A A P P A N N metro water N Separate N Y N N ceftriaxone 7days 3days 8days 3days 11.9 6700 72.6 19.7 7.1 0.1 0.5 2.63 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
devanandhana 9 F 7 intermittent A A A A A P A P P A P A A A N P P P A A A A P A P P A Y N metro water N common Y Y N N ceftriaxone 14days 12days 15days 3days 11.3 5000 80.9 15.5 2.8 0.5 0.3 65000 >1:160 >1:160 S.typhi S S S S S S S.typhi N N N
krithika 12 F 7 intermittent A A A A A P A P P A P A P A N P P A A A A A A A P A A Y N metro water N common N Y N N ceftriaxone 7days 4days 10days 3days 11.6 4800 52.1 43 4.8 0 0.1 1.96 >1:160 >1:160 S.typhi S S S S S S sterile N N N
smruthi 2 F 5 intermittent A A A A A A A P A A P P A A N P P P A A A A P P P P A N N mineral water N Separate N N N Y ceftriaxone 7days 2days 9days 2days 11.5 11300 63.4 28.9 7.2 0.1 0.4 2.47 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
sneha 6 F 8 intermittent A A A A A P A P P A A A A A Y P P P P A A A P A P P A N N metro water N Separate N N N N ceftriaxone 7days 5days 8days 2days 9.6 6300 49.6 36.7 11.9 0.5 1.3 1.93 >1:160 >1:40 sterile 0 0 0 0 0 0 0 0 0 0
yogesh 2 M 7 intermittent A A A A A P A A P A A A A A N A P A P A A A A A P P A N N metro water N Separate N N N N ceftriaxone 7days 4days 8days 2days 9.5 `12000 51.5 39.4 8 0.1 1 2.46 >1:160 >1:160 S.typhi S S S S S S sterile N N N
pritika 2 F 11 intermittent A A A A A A A P A A A A A A N P P P P A A A A A P p A N N metro water N common Y N N Y ceftriaxone 7days 2days 7days 1day 9.1 7100 25.9 61.6 11.6 0.2 0.7 2.36 >1:160 >1:160 S.typhi S S S S S S sterile N N N
ganesh 2 M 5 intermittent A A A A A P A A A A A A A A N A P A P A A A A A P A A N N metro water Y common N N N N ceftriaxone 7days 3days 8days 4days 10.6 9400 46.8 36.5 16 0.3 0.4 1.96 <1:20 <1:20 S.typhi S S S S S S sterile N N N
parthiban 12 M 7 intermittent A A A A A A A P P A P A A A N P P P P A A A A P P P A N N mineral water N common N N N N ceftriaxone 7days 4days 11days 5days 10.9 5700 83.9 13 3.1 0 0 1.5 0 0 S.typhi S S S S S S sterile N N N
sethupriya 8 F 9 intermittent A P P A A P A P A A P A P A N P P P P A A A A A P P A N N metro water Y Separate N N N N ceftriaxone 7days 3days 8days 1day 10.1 4100 38.1 54 7.9 0 0 1.55 >1:160 >1:40 S.typhi S S S S S S sterile N N N
rakesh 6 M 3 intermittent P A A A A P A P A A A A A A N P P A P A A A A A P P A N Y metro water N common N Y N N ceftriaxone 7days 4days 10days 4days 10.5 5000 82 15 2.8 0 0.2 3 <1:!60 <1:20 S.typhi S S S R S S sterile Y N N
megala 4 F 7 intermittent P A A A A P A A P A A P A A Y P P P P A A A P P P P A N N metro water N common N Y N N ceftriaxone 7days 2days 7days 1day 10 5800 42.2 52.3 5.5 0 0 1.5 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
archana 10 F 5 intermittent P A P A A P A P P A A A A A N P P P P A P A A A A A A N N metro water N common N N N N ceftriaxone 7days 3days 10days 3days 12.5 11100 74.7 18.5 5.9 0.1 0.8 2.9 0 0 S.typhi S S S S S S sterile N N N
malar 4 F 25 intermittent P A A A A P A P P A A A A A Y P P P P A A A P A P P A N N mineral water N common N N N N ceftriaxone 7days 4days 9days 2days 8.4 18700 24 63.9 12.1 0 1 1.5 <1:20 >1:160 S.typhi S S S S S S sterile N N N
mounica 10 F 7 intermittent A A P A A P A A A A A A P A Y A P A A A A A A A P P A Y N metro water N Separate N Y N N ceftriaxone 7days 3days 7days 3days 12.5 6100 59.7 35.4 4.9 1.89 0 0 0 0 S.typhi S S S S S S sterile N N N
karthikeyan 10 M 5 intermittent P P A A A P A P P A A A A A Y P P P A A A A A A P P A Y N metro water N Separate N N N N ceftriaxone 7days 5days 11days 5days 11.7 10100 86.3 11.2 1.6 0 0.9 1.58 >1:40 >1:20 S.typhi S S S S S S sterile N N N
balamurugan 3 M 10 intermittent P A A A A A A P P A P A P A N P P P P A A A A A P A A Y N metro water Y Separate N Y N N ceftriaxone 7days 2days 9days 3days 9.1 6900 44.7 50.3 5 0.2 0.2 2.29 >1:160 >1:160 S.typhi S S S S S S sterile N N N
silverstom 8 M 14 intermittent P A A A A A A A P A A A A A Y A P P A A A A A P P A A N Y mineral water N Separate N Y N N ceftriaxone 7days 6days 10days 1day 12.6 7700 51.3 32.8 15.1 0.2 0.6 2.71 >1:160 >1:160 S.typhi S S S S S S sterile N N N
karish 2 M 15 intermittent A A A A A A A A A A A A P A N A P A P A A A A A P P A N Y mineral water N Separate N N N N ceftriaxone 7days 2days 10days 3days 7.6 8700 34.5 43.9 18 3 0.6 2.51 >1:40 >1:20 S.typhi S S S S S S sterile N N N
janani 7 F 9 intermittent P A A A A A A A A A A A P A N P P P P A A A A P P A A N N metro water N Separate N N N N ceftriaxone 7days 4days 7days 1day 10.5 6100 54.7 38.6 6.7 0 0 2.73 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
kamalesh 6 M 10 intermittent A A P A A A A P A P A A A A N A P A P A A P A P P A A N N metro water N Separate N N N N ceftriaxone 7days 5days 8days 2days 12 6600 56.4 34.5 7.7 0.1 1.3 3.24 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
shivani 3 F 10 intermittent P A A A A A A A A A A A P A N P P P P A A A A A P A A Y N metro water N common Y N N Y ceftriaxone 7days 6days 10days 3days 10.6 17700 53.1 38.1 8.1 0 0.7 3.85 0 0 S.typhi S S S S S S sterile N N N
shwetha 6 F 7 intermittent P P A A A P A A A A A A P A Y A P P P A A A A A P P A N N mineral water N common N Y N N ceftriaxone 7days 2days 7days 1day 10 4700 53.7 39.9 6.4 0.5 0.3 1.67 0 0 S.typhi S S S S S S sterile N N N
pavithra 11 F 14 intermittent P A A A A P A P A A P A A A N A P P P A A A A A P P A N N mineral water N Separate N Y N N ceftriaxone 7days 2days 7days 1day 12.4 5700 58.7 29 11.9 0 0.4 1.61 0 0 S.typhi S S S S S S sterile N N N
muskan banu 6 F 5 intermittent A P A A A A A P A A P A A A Y A P A P A A A A A P A A N N mineral water N Separate N N N N ceftriaxone 7days 2days 10days 4days 10.9 8300 59 34.2 6.6 0.1 0.1 1.67 <1:20 <1:20 S.typhimoderately sensitiveS S Smoderately sensitiveS sterile N N N
naveen kumar 11 M 4 intermittent A P A A A A A P P A P A A A N A P P A A A A A P P P A N Y metro water N common N N N N ceftriaxone 7days 5days 10days 3days 10 6800 50.5 42 8.5 1 1 1.5 >1:160 >1:80 S.typhi S S S S S S sterile N N N
swetha 11 F 4 intermittent A A A A A A A A P A P A A A Y P P A A A A A A P P A A N N metro water N common N Y N N ceftriaxone 7days 3days 10days 3days 11.7 6700 62.7 24.6 12.2 0.1 0.4 1.9 >1:20 >1:20 S.typhi S S S S S S sterile N N N
rajesh kumar 9 M 11 intermittent A P A A A A A A A A A A A A Y A P P P A A A A A P P A Y N mineral water N Separate N Y N N ceftriaxone 7days 4days 11days 4days 12.6 9900 53.4 28.8 10.7 6.7 0.4 3.77 >1:20 >1:40 s.paratyhi A S S S S S S sterile N N N
dinesh 3 M 5 intermittent A A P A A P A P A A A A A A N A P P P A A A A A P A A N N metro water Y Separate N Y N N ceftriaxone 7days 3days 8days 3days 10.1 10900 66 27 7 0 0 1.91 >1:160 >1:160 S.typhi S S S S S S sterile N N N
harini 9 F 4 intermittent A A A A A A A P A A P A A A Y A P A A A A A A A A A A N N mineral water N common N Y N Y ceftriaxone 7days 3days 11days 5days 10.3 7500 60.8 29.6 9.6 0 0 2.99 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
sanjay manohar 7 M 7 intermittent A A A A A A A P A A A A P A Y P P A A A A A A A P P A N N metro water Y Separate N N N N ceftriaxone 7days 3days 8days 3days 11.3 3800 47.2 42.4 8.9 0.9 0.6 2.42 <1:20 <1:20 S.typhi S S S S S S sterile N N N
mencila 11 F 10 intermittent P A A A A P A A A A A A A A N A P A A A A A A A A A A Y N metro water N common N Y N N ceftriaxone 7days 4days 10days 3days 11.8 8500 50 42 7.2 0.1 0.7 0.79 >1:160 >1:160 sterile 0 0 0 0 0 0 0 0 0 0
iniya 6 F 5 intermittent A A A A A A A P P A P A A A N A p A A A A A A P P P A N N metro water N common Y N N Y ceftriaxone 7days 3days 8days 3days 11.1 5900 48.5 39.3 11.5 0.1 0.6 1.2 >1:160 >1:160 S.typhi S S S S S S sterile N N N
abubakkar siddiqi 4 M 10 intermittent A A A A A A A A A A A A A A N P P P P A A A A A P P A Y N metro water N common N Y Y N ceftriaxone 7days 4days 10days 3days 10 8800 40.3 52.2 7.5 0 0 2.73 >1:160 >1:160 S.typhi S S S S S S sterile N N N
harish 11 M 10 intermittent A A A A A P A P A A A A A A Y A P P A A A A A P P A A N N Metro water N Separate N Y N N ceftriaxone 7days 3days 9days 2days 11.3 8600 51.4 38.6 9.2 0.1 0.7 3.3 >1:160 >1:160 S.typhi S S S S S S sterile N N N
meena 2 F 5 intermittent P A A A A P A A P A A A A A N P P P P A A A A A P P A N N Metro water N Separate N N N N ceftriaxone 7days 5days 11days 5days 10 13900 38 50 11 0.3 0.8 2.36 0 0 S.typhi R R R R S R sterile Y Y Y
jayashree 10 F 9 intermittent A A A A A A A P P A P A A A N P P P A A A A A A P P A N Y Metro water N Separate N N N N ceftriaxone 7days 4days 9days 2days 11.6 7400 54 40 3 3 0 2.57 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
devika 2 F 7 intermittent A A A A A A P P A P A A A A N P P P P A A A P A P P A N N Metro water N Separate N N N N ceftriaxone 7days 5days 9days 2days 9.5 8400 62 31 6 0.7 0.7 1.4 >1:160 >1:160 S.typhi S S S S S S sterile N N N
rithesh 2 M 6 intermittent A A A A A P A A A A A A A A N P P P P A A A A A P A A N N Metro water N Separate N N N N ceftriaxone 7days 4days 9days 2days 10 14200 46.5 46 6.5 0.2 0.8 1.5 >1:160 >1:160 S.typhi S S S S S S sterile N N N
avinashi 8 F 7 intermittent P A A A A A A A A A P A A A N P P P A A A A A A P A A N N Metro water N Separate N N N N ceftriaxone 7days 3days 8days 1day 11 7600 50 40 8 1 0.9 1.3 >1:160 >1:160 S.typhi S S S S S S sterile N N N
yogesh 5 M 5 intermittent A A A A A A A A A A A A A A N A P P P A A P A A P P A N N Mineral water N Separate Y N N N ceftriaxone 7days 6days 10days 2days 10.6 4300 51.7 36.1 11.7 0.1 0.4 2.18 >1:160 >1:160 S.typhi S S S R S R sterile Y N Y
makbul khan 10 M 9 intermittent P A A A A P A P A A P A A A N P P P A A A A A A P P A Y N Metro water N common N Y Y Y ceftriaxone 7days 5days 7days 1day 12 6100 62 25.1 12.3 0.1 0.5 2.49 >1:160 >1:160 S.typhi S S S S S S sterile N N N
vijay 6 M 15 intermittent P A A A A P A A A A P A P A Y A P A P A A P A A P A A N N Metro water N common N N Y N ceftriaxone 7days 3days 10days 4days 10.2 4800 52.6 39.6 7 0.1 0.8 2.44 >1:160 >1:160 S.typhi S S S S S S sterile N N N
aruna 7 F 7 intermittent P A A A A A A P A A P A P A N A P A A A A P A P P P A N N Mineral water N common N N N N ceftriaxone 7days 5days 9days 3days 11.6 12000 54.9 36.4 8.2 0.2 0.3 1.85 >1:160 >1:160 sterile 0 0 0 0 0 0 sterile 0 0 0
vinayak 4 M 4 intermittent P A A A A A A P P A A P A A N P P P P A A P A A P A A N N Metro water Y Separate N Y N N ceftriaxone 14days 12days 17days 6days 8.1 7500 39.7 44.8 14.9 0 0.6 2.27 >1:160 >1:160 S.typhi S S S S SModerately sensitivest rile N N N
saravanan 4 M 4 intermittent P A A A A P P A A A A A A A N A P A P A A A A P P P A Y N Metro water N Separate N N N N ceftriaxone 7days 3days 10days 4days 10.9 5900 36 51.8 9.8 1.5 0.9 2.86 0 0 S.typhi S S S S S S sterile N N N
jayesh 7 M 10 intermittent P P A A A P A A A A A A A A N A P P P A A A A A P P A N N Metro water Y common N N N N ceftriaxone 7days 3days 9days 2days 11 6200 42 44.2 10.7 3 0.1 2.36 >1:160 >1:80 S.typhi S S S S S S sterile N N N
rahul 6 M 7 intermittent P P A A A A A A A A A A P A Y A P A A A A A A A P A A Y N Metro water N Separate N Y Y N ceftriaxone 7days 4days 9days 2days 11.1 6500 36.4 49.1 10.9 2.8 0.8 3.15 0 0 S.typhi S S S S S S sterile N N N
sarathy 10 M 10 intermittent P P P A A A P A P A P A A A Y P P P A A A A A A P P A N N Mineral water N Separate N N N N ceftriaxone 7days 4days 11days 5days 11.9 5900 50.4 41.2 7.9 0.1 0.4 2.09 0 0 S.typhi S S S S S S sterile N N N
crossover to
ceftriaxone/
prolonged
treatment with
ceftriaxone
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
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N
N
N
N
N
N
N
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N
N
N
Y
N
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N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
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N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
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N
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N
N
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N
N
N
N
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ANNEXURE - I
STUDY PROFORMA
Name:
Age:                                 Sex:                           DOB :
Address/Phone number:
School:
Insurance number:
Date of admission:                                     Date of discharge:
Diagnosis:
History:
? Fever :
a. Duration -
b. Pattern -
c. Chills/Rigors -
d. Response to antipyretics -
? Headache :
? Myalgia :
? Altered sensorium :
? Seizures :
? Anorexia :
? Loss of weight :
? Vomiting :
? Diarrhoea :
? Constipation :
? Abdominal pain :
? Distension of abdomen :
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? Cough :
? Breathlessness :
Treatment history:
Examination:
? Toxic :
? Febrile/ afebrile :
? Hydration :
? Coated tongue :
? Glossitis :
? cheilitis :
? pallor :
? icterus :
? Vitals  PR
            RR
            BP
? Skin (rose spots) :
? Lymphadenopathy :
? CVS :
? RS :
? Abdomen :
a. Distension -
b. Tenderness -
c. Hepatomegaly -
d. Splenomegaly  -
e. Fluid/tympanitic note -
f. Bowel sounds -
? CNS :
           Others:
Complications if any:
Anthropometry:    Weight -                           Height -
MAC -
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Family & Socioeconomic history:
? Any other member/sibling affected :
? Anyone in the neighbourhood :
? Water supply (Potable/not) :
? Boiled /not :
? Sanitary latrine :
? Immunisation (Typhoid) :
? Diet (Salads/eating out) :
? Past history of typhoid in mother :
? Past history of typhoid in the child :
? Food handling habits in the mother :
Treatment given:
? Medication,  route & dose :
? Duration of therapy :
? Time taken for response :
? Duration of hospital stay :
? Mean duration at diagnosis :
? Diagnosed on what day of fever :
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Investigations:
Hb
TLC
DLC      N
             L
            M
            E
            B
platelets
LFT    TSB
          D
          I
         SGOT
        SGPT
        ALP
Widal    H
              O
Blood culture
Urine culture
Stool culture
Drug
sensitivity
Resistance
Stool culture
after 1 month
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ANNEXURE - II
KEYWORDS
MDRST:      Multi drug resistant Salmonella typhi
NARST:       Nalidixic acid resistant Salmonella typhi
CBC:            Complete blood count
Hb:               Hemoglobin
TLC:            Total leucocyte count
SD:              Standard deviation
SE:              Standard error
MIC:           Minimum inhibitory concentration
C/S:             Culture sensitivity
IV:               Intra venous
OD:             Once daily
BD:              Twice daily
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ANNEXUIRE - III
CONSENT FORM
I, ……………………., have read the information in this form (or it
has been read to me). I was free to ask any questions and they have been
answered. I am over 18 years of age and, exercising my free power of
choice, hereby give my consent for my child to be included as a
participant in the study called "Effectiveness of Azithromycin in
treating uncomplicated Enteric fever as compared to parenteral
Ceftriaxone” : An Experimental study, ESI-PGIMSR, KK Nagar,
Chennai, 2012-2013.
(1) I have read and understood this consent form and the information
provided to me.
(2) I have had the consent document explained to me.
(3) I have been explained about the nature of the study.
(4) My rights and responsibilities have been explained to me by the
investigator.
(5) I agree to cooperate with the investigator
(6) Currently I’m not participating in any research study.
(7)  I  am  aware  of  the  fact  that  I  can  opt  out  of  the  study  at  any  time
without having to give any reason and this will not affect my future.
(8) I hereby give permission to the investigators to release the
information obtained from me as result of participation in this study to the
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regulatory authorities, Government agencies, and ethics committee. I
understand that they may inspect my original records.
(9) My child’s identity will be kept confidential if my data are publicised.
(10) I have had my questions answered to my satisfaction.
(11) I have decided to be in the research study.
I am aware, that if I have any questions during this interview, I should
contact at one of the addresses listed above. By signing this consent from,
I attest that the information given in this document has been clearly
explained to me and understood by me.
As I was not able to read, the consent form has been read out to me by the
investigator and all my questions have been answered. I give my consent
with my free will.
Name of Participant________________   Signature of Participant
___________________
Date:
Name of witness____________                  Signature of witness
_____________
Date:                                                            Thumb print of participant
SIGNATURE OF THE INVESTIGATOR:
DATE:
